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Introduction: Deafness is the most common sensory disability, occurring in approximately
2 per 1000 births in the developed world and up to 6 per 1000 births in South Africa. It has
long-term detrimental impacts on a child's well-being and social  life. Early detection is
associated with better outcomes for the child. Although deafness is a highly heterogeneous
condition, it has been found that mutations in the GJB2 gene encoding connexin 26 (CX26)
are responsible for a large proportion of deafness cases in Europeans and Asians. To date,
there have been few studies examining the genetic causes of deafness among Africans. We
investigated the significance of mutations in two connexon (CX) coding genes on deafness
among Africans.
Methods: Patients  were  recruited  from both  Cameroon  and  South  Africa.  The  cohort
consisted of patients with recessive, non-syndromic, sensorineural deafness of unknown or
putative  genetic  origin  (N  =  217),  two  patients  with  keratitis-icthyosis-deafness  (KID)
syndrome, known to be due to mutations in GJB2 (CX26), and healthy, population-matched
controls (N = 81). DNA, extracted from either blood or saliva, was used for genotyping the
coding regions of the GJB2 (CX26) and GJA1 (CX43) genes using PCR and sequencing.
The  data  was  compared  to  that  generated  by  the  1000  Genomes  Project  enabling  the
construction of a phylogenetic tree and the use of Principal Components Analysis (PCA) to











Results: Our results confirm the role for the p.(D50N) mutation in  GJB2 (CX26) in KID
syndrome. However, among non-syndromic deafness cases, only two mutations in  GJB2
(CX26)  were  found,  both  in  the  heterozygous  state,  in  two  unrelated  patients.  These
mutations alone could not explain the hearing loss in these patients. Subsequent sequencing
of  the  GJA1 (CX43)  gene  did  not  yield  any  mutations.  No  statistically  significant
differences were observed between cases and controls overall. However, among the South
Africans, they were significant differences in  GJB2 (CX26) haplotypes (P = 0,03). Using
PCA and the phylogeny, samples generally grouped together according to their geographic
origin, with GJB2 being more discriminatory compared to GJA1.
Discussion:  The  observation  of the  p.(D50N)  mutation  in  GJB2 (CX26)  in  the  KID
syndrome patients points to it not being population-specific, as this mutation is the most
frequent in all populations. Contrary to what is reported in Europeans and Asians, our data
confirm that mutations in  GJB2 (CX26) do not explain deafness in African patients with
non-syndromic deafness. Our investigation into variations of  GJA1 (CX43) similarly did
not reveal any mutations. Our findings support the hypothesis that there are likely to be
other genes of importance in deafness among Africans, which have yet to be described. 
Conclusion  And Perspective:  Our  results  show that  neither  GJB2 (CX26)  nor  GJA1
(CX43) is significantly associated with non-syndromic deafness in Africans. Future studies
may benefit  from massively parallel  sequencing,  such  as  whole  exome  sequencing,  as
opposed  to  single  gene  approaches,  in  order  to  unravel  the  genetic  aetiology  of  non-












Deafness is a global problem but is most serious in the developing world. The United States
and Europe have prevalence rates of childhood hearing loss of less than 2 per 1000 live
births.1,2 In  the developing world,  the numbers are  greater  with 7 per  1000 children in
Nigeria3 and 5,5 per 1000 live births in South Africa4 suffering from deafness. Deafness is a
highly complex condition caused by both genetic and environmental factors as well as a
combination of the two.5 
About 25% of permanent childhood deafness in the US and Europe is  hereditary,  with
another  25%  acquired  and  around  half  of  unknown  aetiology1,6,7.  Aetiological  studies
conducted in Africa paint a very different picture. Recent work in Cameroon shows the
aetiology  of  hearing  loss  to  be  15%  genetic,  52%  acquired  and  33%  unknown,  with
meningitis accounting for 34% of all cases.8
Globally, it has been found that genetic hearing loss is caused primarily by mutations in gap
junction beta 2 (GJB2) which encodes connexin 26 (CX26). The major mutations in GJB2
have been shown to be population-specific, due to founder effects, and include c.35delG
affecting  Caucasians,9 c.167delT  affecting  those  of  Ashkenazi  Jewish  ancestry10 and
c.235delC  affecting  East  Asians.11 In  contrast,  studies  of  GJB2  in  Africans  or  African
Americans have not shown a large contribution to deafness and that the common mutations
are only present at low frequencies12,13,14. Mutations in other connexins are also known to
cause deafness, with GJA1 occasionally being included in diagnostic testing after an early
paper suggested its involvement in deafness in patients of African ancestry.15
This study aimed to ascertain the significance of connexin mutations in GJB2 and GJA1 in
a sample of African patients from both Cameroon and South Africa with recessive, non-
syndromic deafness. In addition, we included two patients with a rare syndromic condition
for genotyping as the disease was known to be caused by GJB2 mutations and had not been












2.1- Normal Hearing Function16,17 
The ear is divided into three sections, the outer, middle and inner ear, all of which play an
important  role  in  hearing.  The structure of the ear  is  presented in  Figure  1.  In normal
hearing, sound is collected by the outer ear, amplified by the middle ear and converted to a
nerve impulse in by the inner ear.
The pinna collects sound and directs  it  down the ear canal to the tympanic membrane.
Sound is  then conducted through the tympanic membrane and the three ossicles to  the
cochlea. During this period the sound is amplified due to the relative differences in size
between the pinna, tympanic membrane and the ossicles. The ossicles act as a series of
levers which further amplifies the sound. 
2










As the stapes, the third ossicle, vibrates, it transfers that movement to the perilymph of the
cochlear. The cochlear (Figure 2) is divided into three tunnels, the scala vestibuli and scala
tympani, which are connected and both filled with perilymph, and the scala media which is
closed  and  filled  with  endolymph.  The  hair  cells,  which  trigger  the  nerve  pulses,  are
mounted on the basilar membrane in the scala media.  As the basilar  membrane moves,
because of the movement of the perilymph, it causes the hair cells to stimulate the neurons.
This stimulus is caused through the change in action potential due to an influx of potassium
ions, through mechanically-gated ion channels, into the hair cell. The nerve impulses then
travel away from the cochlea, via the auditory nerve, to the brain where they are interpreted
as sound. 
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Hearing loss is a condition where an individual's ability to hear is reduced for any reason. It
has far-reaching effects on both individuals and their families, leading to stress, increased
risk of abuse, reduced educational performance and lowered earning potential.18 The earlier
it is detected, the sooner treatment can begin and the less of an effect it will have. Hearing
loss is often grouped according to the severity of the condition, but the criteria for each
category differs slightly from study to study which can make comparisons difficult. Table 1
gives the categories of hearing loss according to the World Health Organisation (WHO) but
the American Speech-Language-Hearing Association (ASHA), for example, uses slightly
different criteria.19 







0 – No 
impairment
25 dB or better (better 
ear)
No or very slight hearing 
problems. Able to hear 
whispers.
1 – Slight 
impairment
26 – 40 dB (better ear) Able to hear and repeat 
words spoken in normal 
voice at one metre.
Counselling. Hearing aids
may be needed.
2 – Moderate 
impairment
41-60 dB (better ear) Able to hear and repeat 
words spoken in raised 
voice at one metre.
Hearing aids usually 
recommended.
3 – Severe 
impairment
61-80 dB (better ear) Able to hear some words 
when shouted into better 
ear. 
Hearing aids needed. If 
no hearing aids available, 
lip-reading and signing 
should be taught.
4 – Profound 
impairment, 
including deafness
81 dB or greater (better
ear)
Unable to hear and 
understand even a shouted
voice.
Hearing aids may help 
understanding words. 
Additional rehabilitation 













2.2.1- Classification Of Hearing Loss
The  Palo  Alto  Medical  Foundation  describes  three  types  of  hearing  loss,  conductive,
sensorineural and mixed.21 Conductive hearing loss concerns the outer and/or middle ear
and  occurs  when  sound  is  prevented  from  easily  passing  through  to  the  inner  ear.
Sensorineural hearing loss occurs when there is a problem with the inner ear, so that the
nerves or sensory cells do not transmit the sound to the brain. Mixed hearing loss is when
there is a combination of both conductive and sensorineural hearing loss. If the hearing loss
occurs with no other symptoms or signs it is referred to as non-syndromic. However, if
there are other features present, it is known as syndromic hearing loss.
Depending on the time when hearing loss presents, it can be described as either acquired or
congenital. Congenital hearing loss is that which is present when a baby is born, though it is
not necessarily genetic. Acquired hearing loss is that which occurs after birth, either from
delayed genetic effects, the environment or natural ageing. Also referring to the timing of
hearing loss are the categories prelingual and postlingual. These apply depending on when
hearing  loss  occurred  with  respect  to  language  acquisition.  All  congenital  deafness  is
prelingual.
There are also many other descriptors of hearing loss that are useful to understanding how a
particular  individual  is  affected.22 It  might  be that  the  hearing loss  only affects  certain
frequencies, such as high-frequency hearing loss or low-frequency hearing loss. This can be
seen on an audiogram such as in Figure 3. The graph shows severe to profound impairment
of hearing at all frequencies but particularly at the higher frequencies. In a healthy person,
the graph will be a flat line, running along the very top, which would indicate no reduction











Hearing loss may occur in only one or both ears or there could be a different amount of
hearing loss in each ear. If the ears have the same magnitude of hearing loss and the same
cause then the hearing loss is symmetrical. If the hearing loss differs in severity or cause
then it is asymmetrical. Some tests may not detect asymmetrical hearing loss and the degree
of hearing loss is measured according to the ability of the better ear.
Hearing loss may occur suddenly or it may be progressive and increase in severity with
time, for example hearing loss caused by noise or old age. Hearing loss may also be stable
over time or fluctuate with the degree of hearing loss increasing or decreasing over a period
of time. The epidemiology of hearing loss is similarly variable.
6
Figure 3: Example of an audiogram. In this case, the audiogram tracks average hearing










2.2.2- Epidemiology Of Congenital Hearing Loss
The prevalence rate of congenital hearing loss in Europe is approximately 1,47 per 1000
births.2 A review of children screened for hearing loss in the United States in 2004 found
that 1,1 per 1000 infants had permanent hearing loss.1 In China, a 2010 study showed the
prevalence of congenital deafness in the Hubei province to be 0,5 per 1000 births23 and a
trial in Shanghai found a rate 1,5 per 1000 births.24 Japan, although a developed country,
has a higher rate of hearing loss than Europe and the US with about 3 per 1000 births
suffering from congenital  hearing loss.25 The rates  of  congenital  hearing loss  are  much
higher in the developing world, with an estimated average of 6 per 1000 live births in Sub-
Saharan Africa developing hearing loss in the first few weeks of life.18 A study of infant
screening programmes in Lagos, Nigeria, found that the incidence of hearing loss was 7 per
1000 individuals.3 
The rate of congenital and early-onset hearing loss for South Africa has been estimated at
5,5 per 1000 individuals, much higher than in Europe and America and more in line with
other Sub-Saharan countries.4 This is most likely due to poor health care as the prevalence
rate reported in the private health sector is 3 per 1000, compared to 6 per 1000 in the public
health sector. A community screening programme in the Western Cape found 4,5 per 1000
infants screened during vaccination.26 
2.2.3- Detection Of Hearing Loss
Screening for hearing loss in newborns is standard practice in some countries and is the
most effective way to detect hearing problems and reduce the negative effects of hearing
loss. Testing may also be conducted at schools. Outside of those situations, hearing tests are
recommended for people who find they have trouble hearing during daily life or for a child












South Africa does not have a national, neonatal screening programme and, at best, only
7,5%  of  public  hospitals  provide  screening  for  hearing  loss  with  only  1%  providing
universal screening.4 The situation is even worse for neighbouring countries and it has been
found that many doctors have not had contact with deaf children and do not respond to
parental  concerns  appropriately.18 In  the  South  African  private  health  sector  53%  of
hospitals  with  obstetric  units  provide  hearing  screening on request  but  only 14% offer
universal screening.27
There are a number of different tests for hearing loss that operate on a variety of principles
and may be suitable for different situations.  These tests  include pure tone audiometry5,
speech testing,28 otoacoustic emissions,5,29 auditory brain-stem response5,29 and immittance
testing.5,30 
2.2.4- Aetiology Of Childhood Hearing Loss
There are many causes of hearing loss such as loud noises, physical trauma, infections,
drugs and genetic causes. The most recent review of the aetiology of childhood hearing loss
was  performed by Korver  et  al.,  primarily  based  on data  from Western  countries,  and
showed 48,3% of cases of hearing loss were of unknown cause, 30,4% were genetic and
19,2% were acquired.7 It also found 9,8% of cases were non-syndromic and 11,8% were
syndromic. This is in agreement with Mehra et al.'s review of the aetiology of hearing loss
in America.1 
Krover  and  Mehra  et  al.'s  reviews  show  a  different  result  from Morzaria  et  al.,  who
examined studies published in English and found the biggest causes of hearing loss could
be classed as unknown (37,70%) followed by non-syndromic genetic (29,21%), prenatal
(12,04%), perinatal (9,62%), postnatal (8,21%) and syndromic genetic (3,15%).6 This could
be due to different criteria used for the inclusion of studies as they all used papers published











A 1997 review of childhood hearing loss in sub-Saharan Africa found that the main cause
of hearing loss was infection,  particularly meningitis  and measles,  with very few cases
attributed to a genetic aetiology.31 There were more cases of genetic hearing loss, mostly
syndromic,  in  Zimbabwe  and  South  Africa.  It  is  worth  noting  that  very  little  genetic
analysis was done in the African countries.
This illustrates that the frequencies of these causes are not absolute and will vary by place
and time. As we learn more about the causes, particularly genetic causes, of hearing loss
and  develop  better  tests  we will  see  a  reduction  in  cases  of  unknown aetiology.  With
improved health care there will also be a reduction in the number of cases of hearing loss
caused by disease and an increase in the proportion attributable to genetics.
2.2.4.1- Non-Genetic Causes
As medicine has improved it has led to a reduction in the non-genetic causes of hearing
loss. When Morzaria et al compared their 1966-1989 cohort with those from 1990-2002
they found changes in the aetiology of hearing loss, such as Rubella dropping from 5,77%
to 1,28% while asphyxia and prematurity rose from 1,98% and 1,38% to 2,57% and 2,84%
respectively.6 Roizen  observed  an  increase  in  the  proportion  of  deafness  in  neonatal
intensive care units due to low birth weight and perinatal factors from 2% in the 1960s and
'70s to 17% in 1983-1992.32 
It must be remembered though that those figures are for the developed world. While there
are reductions in disease due to vaccinations, these are not always available in Africa. The
1997 review mentioned above paints a much grimmer picture for the developing world,
with meningitis and measles accounting for up to 31% and 19% of acquired hearing loss
respectively.31 In many African countries, malnutrition of children is a real problem that is











treatments  for  disease  have  been  developed,  researchers'  interest  in  deafness  has  been
focussed on the genetic causes of deafness.
2.2.4.2- Genetic Causes
Genetic causes are thought to contribute up to 30% of cases of hearing loss worldwide, vary
by population group and can be divided both by how hearing loss presents and by the mode
of inheritance. There are differing figures for the relative proportions of syndromic and
non-syndromic hearing loss but both have multiple aetiologies. Syndromic hearing loss is
made up of more than 400 different syndromes34 and, by July 2013, the Hereditary Hearing
Loss website35 listed a total of 65 genes involved in non-syndromic hearing loss. When
considering mode of inheritance (Figure 4), Hone & Smith claimed that 75-80% of hearing
loss  was  recessive,  20%  dominant,  2-5%  X-linked  and  a  very  small  number
mitochondrially  inherited.34 Bayazit  and  Yılmaz  described  approximately  the  same
proportions in their 2006 review.36 
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Mitochondrial mutations are the rarest cause of hearing loss. However, they are particularly
important in a South African context as they contribute to aminoglycoside-induced hearing
loss. Aminoglycosides are used in the treatment of tuberculosis and so individuals carrying
mitochondrial  mutations  have  an  increased  risk  of  permanent  hearing  loss  if  treated
inappropriately.
On the other end of the spectrum, recessive genetic conditions are the largest contributor to
genetic hearing loss and, of the genes involved in recessive hearing loss, the most important
is  GJB2, encoding connexin 26. It is one of the leading causes of hearing loss in many
populations and, depending on the specific mutation, can be inherited in either a recessive













2.3.1- Structure And Function
There are 21 human connexins,37 which are expressed in almost every cell.38 The connexin
proteins  are  named according to  their  weight.37 Thus,  connexin  26  is  a  protein  with  a
molecular weight of 26 kDa. If there are multiple proteins with similar mass then they are
distinguished by the use of a decimal point, such as with CX30 and CX30.3. 
The names of the genes encoding connexins are determined according to how they are
grouped and the order  of their  discovery and all  begin with "GJ" which refers to "gap
junction."37 Gap junctions are intercellular channels that allow ions, secondary messengers
and small metabolites to be exchanged by adjacent cells. The proteins that make up gap
junctions fall into one of three groups; connexins in chordates, innexins in non-chordates
and pannexins in vertebrates.38 The two major groups of connexins are the alpha and beta
connexins based on sequence similarity of the cytoplasmic loop. So, GJB2 was the second
beta connexin gene to be identified. The actual value of the grouping is disputed, however,
and genes are being renamed to fit a phylogenetic classification.37 
Connexins all share a basic structure, shown in Figure 5, with four transmembrane domains
and  two  extracellular  loops  which  play  a  role  in  protein  docking  and
recognition.38 Connexins  use  the  extracellular  domains  to  form  gap  junctions  with
connexins in neighbouring cells. Most of the connexin structure is conserved, although the











Connexins form intercellular channels by combining in groups of six to form a structure
called a connexon.17 Connexons from adjacent cells join together to form gap junctions.
These gap junctions have variable properties as connexons can consist of just a single type
of  connexin,  described  as  homomeric,  or  a  combination  thereof,  heteromeric,  and
connexons  in  adjacent  cells  may  be  composed  by  the  same,  homotypic,  or  different
proteins, heterotypic.38 These variations in structure and assembly are illustrated in Figure
6.
13
Figure  5: Generalised structure of  a connexin and the putative function of
each domain. M1–M4: transmembrane domains 1–4; E1/E2: extracellular domains












GJB2 is located on chromosome 13 and codes for the gap-junction protein connexin 26.
Connexin 26 is invol ed in the transport of potassium ions and other small molecules and is
expressed in the cochlea, shown in Figure 2, skin, liver and placenta.38,39,40 The structure of
connexin 26 is shown in Figure  7 where one can see that there are few mutations in the
intercellular loop or C-terminus. It is also worth noting that syndromic deafness mutations
are all dominant.
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Figure  6: Illustration of how connexins join to form connexons, how connexons
join to form gap junctions and the various combinations that can occur. (Source:










GJB2 has been identified as a major cause of autosomal recessive hearing loss in several
population  groups,  although  the  specific  mutations  contributing  to  hearing  loss  are
generally  population-specific.  GJB2 has  also  been  linked  to  other  diseases  such  as
autosomal dominant deafness and syndromic diseases with a combination of hearing loss
and  skin  disorders  such  as  Vohwinkel  syndrome  and  keratitis-icthyosis-deafness
syndrome.41 
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Figure 7: Structure of connexin 26 with positions of deafness-associated mutations










It is believed that mutations in Connexin 26 affect its ability to transport potassium ions and
therefore regulate endocochlear potential, which is required for nerve impulses involved in
hearing, but the mode of action is not definitive. It is possible that it is involved in transport
of other metabolites which may also have an effect on hearing.39 This is supported by some
studies that have found certain mutations to have no effect on the ability to transport ions
but a reduced ability to transport other molecules such as glucose.42 
2.3.2.1- Molecular Epidemiology Of GJB2
2.3.2.1.1- Global Mutation Spectrum
A lot of focus is given to studies of  GJB2 performed on Caucasian populations and its
contribution to hearing loss in that context. However, more broadly, it has been shown that
the contribution of  GJB2 to hearing loss differs from population to population and, even
more  importantly,  the  actual  mutations  contributing  to  hearing  loss  differ  between
populations.
GJB2 was  first  associated with deafness  in  patients  with dominant,  syndromic,  genetic
deafness, however, in 1997, it was implicated in recessive, non-syndromic deafness in a
consanguineous  Pakistani  family.40 The  mutation  detected  was  p.(W77X)  and,  after
screening another  two families,  a  second mutation,  p.(W24X),  was  discovered.  A later
study on Pakistani patients found GJB2 mutations in 16,6% of alleles, although only 6,1%
were  pathogenic,  and  also  found  p.(W24X)  and  p.(W77X)  to  be  the  most  common
mutations.43 Similar  results  have been found in the British Pakistani community with a
study finding that 7,69% of hearing impaired individuals had pathogenic GJB2 mutations
with all of them being homozygous for p.(W24X).44 p.(W24X) is also the most prevalent












When research began to focus on European populations and their descendants in America
the  same  gene  was  found  but  with  different  mutations.  Zelante  et  al.  found  90%  of
chromosomes from Mediterranean patients with non-syndromic, sensorineural deafness had
GJB2 mutations and 60% of chromosomes carried the c.35delG mutation.47 Rabionet found
fewer  GJB2 mutations, in only 37% of hearing loss chromosomes,  but a similarly high
prevalence of the c.35delG mutation, 82% of the mutant chromosomes.48 In America, Green
et al. found 58% of individuals with hearing loss had GJB2 mutations and the carrier rate of
the c.35delG mutation was 2,5%.49 This was extrapolated to give a total  GJB2 mutation
carrier rate of 3% for the mid-Western US. Other studies have given different figures for
the  prevalence  of  GJB2 variations.  Pandya  et  al.  described  GJB2 alterations  in
approximately 33% of alleles, with 31% of the total alleles being pathogenic,50 and Wu et
al.  found nearly 43% of  alleles  have  a  variation.51 There  is  a  consensus  that  the  most
common  mutations  are  c.35delG,  p.(M34T),  and  c.167delT  with  prevalence  rates  of
approximately 24%, 2,2% and 2,7% of alleles respectively. As non-syndromic hearing loss
can be caused by many genes, and even more mutations, a single gene with a few highly
prevalent mutations being responsible for the m jority of deafness was an encouraging find.
When one moves away from the Caucasian populations the mutation spectrum changes,
just like how a different array of mutations was observed in Pakistanis. In East Greenland,
it was found that only around 8% of alleles in individuals with hearing loss had a  GJB2
variant and that  dropp d to about  3% when considering mutations,  including c.35delG,
suggesting GJB2 did not play a major role in hearing loss in that population.52 Similarly in
the Ashkenazi Jews the c.35delG mutation is present but its effect is far less than that of the
c.167delT mutation, which is the most common mutation in that group. This mutation has a











Studies in the Chinese population have found that although GJB2 is an important cause of
hearing loss, with variants in 39% of patients with hearing loss and mutations in 16%, the
c.35delG mutation plays only a tiny role.53 While c.35delG accounted for 0,85% of alleles,
c.235delC and c.299-300delAT accounted for 20% and 4% of alleles respectively. Similar
results were reported by Chen et al. in 2011, with 18% of hearing loss patients having a
GJB2 mutation.54 Chen et al.'s study found c.235delC mutation accounted for 9,7% of the
alleles, the c.299-300delAT mutation accounted for 1,5% and the c.35delG mutation for
0,25%.
2.3.2.1.2- Reported GJB2 Mutations/Variations In Africans
The importance of c.35delG, and even that of GJB2, for deafness in African populations is
questionable. Very little research has been done on non-syndromic sensorineural hearing
loss in African populations, despite the continent containing a large and rapidly growing
proportion of the world's population. Most research on genetic, recessive hearing loss has
been  focussed  on  Caucasian  populations,  yet  research  on  other  population  groups  has
shown  the  mutations  leading  to  hearing  loss  are  population-specific  due  to  founder
mutations.9,10,11 This means that current genetic tests for deafness, which focus on  GJB2,
may not be appropriate for African populations. 
A recent study in South Africa reported no common  GJB2 mutations, the absence of the
GJB6:D13S1830  deletion  and  none  of  four  mitochondrial  mutations  (c.A1555G,
c.A3243G,  c.A7445G,  and  c.T7511C).14 Two  GJB2 variations  were  found  at  high
frequencies, g.3318-34C>T and g.3318-15C>T at 46% and 21% respectively. They were












A study of the Kenyan and Sudanese population found 23% of cases had variations in
GJB2, but less than 4% were located in the coding region of the gene and there were no
controls against which to assess pathogenicity.12 The c.35delG mutation was detected in 3%
of Sudanese individuals, a much lower figure than in Europeans, and not at all in Kenyans.
The g.3318-34C>T and g.3318-15C>T variations detected in South Africa were both found
in the combined Kenyan and Sudanese cohort at frequencies of 13% and 6,5% respectively.
Studies on African Americans have also found low prevalence of common mutations. One
study reported  9% of African American alleles contained  GJB2  variations,  the majority
being c.35delG, compared to 33% of Caucasian alleles.50 A second study found that about
8,7%  of  hearing-impaired  individuals  had  a  polymorphism  in  GJB2  as  well  as  only
polymorphisms in the controls.55 
There  are  two  African  countries  where  GJB2 mutations  have  been  shown  to  play  a
substantial role. They are Tunisia and Ghana. In Tunisia, approximately 17% of families
affected by hearing loss have mutations in the GJB2 gene with c.35delG as the predominant
mutation followed by p.(E47X).56 These results were confirmed by a subsequent study that
found 27% of deaf patients had a GJB2 mutation57 and the most recent, which found GJB2
mutations, 85% of which are c.35delG, in 39% of families.58 This can be explained by the
fact that the Tunisian population is primarily Arab.
In Ghana, around 17% of hearing impaired individuals carry a GJB2 mutation.59 The most
common being  the  p.(R143W)  mutation,  which  has  previously  been  found  in  all  deaf
individuals in one Ghanaian village.60 This mutation is seldom found elsewhere and appears
to represent an African founder effect in Ghana, much like c.35delG in Caucasians9 and













Connexin 43 (CX43) is widely expressed in the human body. This is well-illustrated by the
list  of  symptoms  of  oculodentodigital  dysplasia  (ODDD),  a  rare,  autosomal  dominant
disease caused by mutations in  GJA1, which includes skeletal and tooth malformations,
syndactyly, deafness, mental retardation, dry and scaly skin and other abnormalities.61,62,63 It
should be noted that ODDD is highly variable and many of the features occur infrequently.
CX43 is a major component of gap junctions in the skin,64 where it plays a role in wound
healing.65 It is abundantly expressed in bone cells,66 and is known to be expressed in the
heart. Some studies suggest a relationship between GJA1 and pulse rate67 or that mutations
in GJA1 may contribute to sudden infant death68 while others show GJA1 is not likely to be
important in congenital heart disease.69
 
There have been few studies of CX43 expression in the cochlea, the most important site if it
is involved in hearing loss, but there is good evidence of its expression. Liu et al. gave
preliminary results of CX43 expression in the satellite cells of the spiral ganglion.70 This
was followed up by a more sensitive method of observing CX43 expression and revealed
that the protein was produced in many of the cells making up the organ of corti as shown in
Figure 8.71 The evidence provided by CX43 expression in the cochlea makes it biologically











2.3.3.2- GJA1 And Hearing Loss
After  successfully linking a  number  of  other  gap  junction  mutations  to  deafness,  most
notably with GJB2 and GJB6, researchers turned their attention to GJA1. In 2001, Liu et al.
screened 26 deaf African Americans, 100 controls (split among 40 African Americans and
60 from other races) and 510 deaf probands from other races in a DNA repository. In the
African American cohort, Liu et al. found three individuals homozygous for one change
and one homozygous for a second change, concluding that GJA1 could be a common cause
of recessive deafness in people of African ancestry.15 
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Figure  8: Connexin 43 immunohistochemistry of the cochlea. Arrowheads = basal
cell  layer  of  stria  vascularis;  thin  arrows = pillar  cells;  asterisks  =  covering cell  layer
beneath the basilar membrane; SL = spiral limbus; SP = spiral  prominence; square =










Two  years  later,  in  a  paper  on  occulodentodigital  dysplasia,  Paznekas  et  al.  revealed
personal communication that showed that the results of Liu et al. were due to changes to the
GJA1 pseudogene.61 A study conducted in Turkey of approximately 60 deaf patients and
210 controls found no variations in GJA1.72 At this point there was no evidence of a link
between GJA1 and hearing loss.
Work done in 2007 on Taiwanese patients provided fresh evidence of a link between GJA1
and hearing loss. Yang et al. examined multiple connexins, including connexin 43 and its
pseudogene, in a cohort of deaf patients and found several variants.73 Three polymorphisms
(defined as occurring in both patients and controls) were discovered in the pseudogene, two
of which occurred at a statistically significantly different rate between patients and controls
and only in the homozygous form. Yang et al. also detected two pseudogene mutations,
205T>C (p.(S69P)) and 932delC and one GJA1 mutation, 977C>T (T326I). These were not
highly prevalent, with the exception of the pseudogene mutation 932delC which occurred,
heterozygously, in 6,15% of patients. In addition, they found three synonymous mutations,
one in the pseudogene and two in GJA1.
The three non-synonymous Taiwanese mutations were further tested with a dye transfer
assay.  All  three mutant proteins showed correct trafficking in the cell  but impaired dye
transfer with two showing no dye transfer at all.74 This further supports the link between the
mutations and deafness, however the contribution from GJA1 is likely small as a second
screening of 253 Taiwanese patients with hearing loss found only one GJA1 heterozygote
and no variant in any of the 120 controls.75
In 2012, a study in Iran found another possible, though also unlikely, link between GJA1
and  deafness.76 Three  variants,  c.758C>T  (p.(A253V)),  synonymous  c.717G>A  and
c.3*dupA, were discovered in 4/34 (11,8%) patients and 7/200 (3,5%) controls. All  the











While not linked to any specific mutation,  it  is worth noting that when Paznekas et al.
examined 177 ODDD individuals with known  GJA1 mutations and available phenotypic
data, 26% had conductive hearing loss.77
2.3.4- Syndromic Conditions
2.3.4.1- Overview Of Syndromic Connexin Diseases
While the majority of this thesis is concerned with non-syndromic deafness, it was already
mentioned that two Cameroonian samples that formed an off-shoot of the connexin study
had a syndromic condition, both suffer from KID syndrome. Syndromic deafness is the
term used when deafness presents with a second clinical feature, in the case of connexin
mutations this is usually a skin condition.  GJB2 can cause a number of syndromes that
present with deafness, including keratitis-icthyosis-deafness (KID) syndrome, hystrix-like
icthyosis deafness syndrome, Bart-Pumphrey syndrome and Vohwinkel syndrome.39 GJA1
is involved in the syndromic condition, ODDD, described briefly in 2.3.3.1.
Although non-syndromic hearing loss can be found in both dominant and recessive forms it
has been found that all syndromic hearing loss by connexin 26 is dominant. As the the
common c.35delG mutation in Caucasians leads to a truncated protein and recessive, non-
syndromic  heari g  loss  we  can  assume  that  the  loss  of  connexin  26  does  not  cause
syndromic effects. It is hypothesised that syndromic deafness is caused by mutations which
also affect other proteins.78 There is experimental evidence to support this hypothesis.
It  is  well-known  that  different  connexins  can  form  hemichannels  with  one  another
(heteromeric connexons). Liu et al. showed that not only did connexins 26 and 31 stain at
the same position in the cochlea but that immunoprecipitation with anti-CX31 antibodies
showed reaction with CX31, CX26 and CX30 in Western blotting.79 It has also been shown











conductance of other connexins expressed in the same oocyte.80
2.3.4.2- KID Syndrome
Keratits-icthyosis-deafness Syndrome (OMIM: 148210) is an extremely rare disease that
has  only  been  reported  in  approximately  100  patients  worldwide.  It  has  three  major
symptoms; keratitis, inflammation of the cornea, icthyosis, dry, thickened or scaly skin and
severe sensorineural deafness. Aside from the diagnostic manifestations, the phenotype can
include many other conditions such as increased risk of infection and increased occurrence
of squamous cell carcinoma.81 
It is usually caused by mutations in GJB282,83 which generally occur de novo with the most
common being p.(D50N).84 Interestingly a p.(V37E) mutation in  GJB6 (connexin 30) has
also  been  linked  to  KID  syndrome,  suggesting  there  may  be  more  than  one  genetic
cause.85 That same mutation in GJB6 has also been linked to Clouston syndrome (OMIM:
129500) in a Scottish patient whose skin phenotype overlaps that of KID syndrome.86 The
reason why the same mutation could lead to two different syndromes may be due to the
KID syndrome patient having the GJB6 mutation as well as being homozygous for the p.
(V27I) mutation in GJB2. While the p.(V27I) change in GJB2 is considered non-pathogenic
on its own it has been speculated that perhaps interactions between p.(V37E)-GJB6 and p.
(V27I)-GJB2 lead  to  the  different  observed  phenotypes.  While  discussing  the  overlap
between these connexin diseases it should also be noted that p.(D50N)-GJB6, the same
change that causes KID syndrome in GJB2, can be responsible for Clouston syndrome on
its own.87 
An autosomal recessive form of KID syndrome (OMIM: 242150) has been proposed but
this has not been confirmed with molecular work and, as most cases of KID syndrome arise












Currently  GJB2 mutations  are  considered  to  explain  the  majority  of  cases  of  non-
syndromic, sensorineural hearing loss but there are few studies of  GJB2 on Africans. We
examined GJB2, using Cameroon as a proxy for African diversity as the country has been
shown to contain  high  levels  of  genetic  diversity.88 We also chose to  sample  from the
previously-unstudied Xhosa population of South Africa. In addition, despite very limited
evidence of GJA1 being involved in deafness it is sometimes included in clinical testing for
Black Africans in South Africa.  We present here the results  of the first  study of  GJA1
conducted on Africans. This adds to our knowledge of the genetics of hearing loss in Africa











3- Aim And Objectives
3.1- Aim
The aim was to ascertain the significance of connexin mutations in  GJB2 and  GJA1 in a
sample of African patients from both Cameroon and South Africa with recessive,  non-
syndromic deafness. A secondary aim was to genotype two Cameroonian patients with KID
syndrome, a disease known to be caused by mutations in GJB2.
3.2- Objectives
The aims were achieved through the following objectives:
1. Recruitment  of  Cameroonian  and  Black  South  African  patients  with  congenital,
non-syndromic hearing loss of unknown or putative genetic origin.
2. Extraction  of  DNA,  from either  peripheral  blood  or  saliva,  and sequencing  the
coding  regions  of  GJB2 (CX26)  and  GJA1 (CX43)  in  patients  and  population-
matched controls. 
3. Ascertaining of the role of genetic variation in both  GJB2 and  GJA1 in deafness
among African populations.
4. Comparing sequence  variations  both between patients  and controls  and between













Recruitment  of  patients  from Cameroon  was  approved  by Cameroon's  National  Ethics
Committee, authorisation number N°123/CNE/SE/2010. Ethics approval for this study was
granted by the University of Cape Town's Human Research Ethics Committee, HREC REF:
080/2011. Written and signed informed consent was obtained from all participants, if they
were 18 years or older, or from the parents/guardians with verbal assent from the children.
4.2- Patients And Settings
4.2.1- Procedure 
Patients were recruited from seven of the ten regions of Cameroon, mainly from schools for
the  deaf,  and  those  procedures  have  been  reported  previously.8 Xhosa  patients  were
recruited from a school for the deaf in the Eastern Cape Province of South Africa. 
During recruitment, information on participants' medical and family history was obtained
from the participants themselves, their parents and medical records, depending on which
sources  were  available.  In  the  majority  of  cases,  general  systemic  and  otological
examination was performed as well as an audiological evaluation using either pure tone
audiometry  or  auditory  brain  stem  response  test.  Audiological  test  results  that  were
obtained before admission to schools for the deaf were also reviewed for some subjects.
When  syndromic  deafness  was  suspected,  additional  tests,  when  possible,  were  later











4.2.2- Inclusion And Exclusion Criteria
For the present study, the following inclusion criteria were used for patients:
• Patients of Black African descent with non-syndromic hearing loss as confirmed by
a clinical and audiological report.
• Deafness of putative genetic origin, as revealed by one or more affected member in
the families or consanguinity, or deafness of unknown origin.
• Two patients with KID syndrome, a condition known to be caused by mutations in
the GJB2 gene, were also included for genotyping.
Patients were excluded from the study if they failed to meet inclusion criteria or declined to
participate in the study. Reasons for exclusion were primarily that patients had syndromic
deafness, with the exception of KID syndrome patients, or their hearing loss had obvious
environmental  causes,  mostly  meningitis,  trauma,  prematurity  or  exposure  to  ototoxic
drugs.
Following the above criteria,  194 non-syndromic and two KID syndrome Cameroonian
patients with available DNA samples were recruited from the previously reported cohort.
Forty-four South African patients were prospectively recruited from Efata School for the
Blind and Deaf in the Eastern Cape Province. Upon review of the South African patients'
information sheets, 19 patients were excluded from the study due to suspected syndromic or
acquired deafness, resulting in a final cohort of 25. Although all patients were included in
the GJB2 portion of the study, only a selected subset was included for GJA1. The patients












Healthy and normal hearing controls were recruited from the same population background.
In total, there were 17 South African and 64 Cameroonian controls.
4.3- Molecular Methods
4.3.1- DNA Extraction, Quantification And Integrity Check
DNA was  extracted  either  from  blood,  using  a  modified  version  of  the  salting  out
method,89 or purified from saliva according to the manufacturer's instructions with minor
changes (Oragene® kit; DNA Genotek®, USA). The protocols are available in appendices
I.VI and I.VII. 
All  DNA samples  were subjected  to  spectrophotometry to  determine  concentration and
purity  and  gel  electrophoresis  to  assess  DNA integrity  before  use.  Spectrophotometric
measurements  were carried  out  with  a  Nanodrop ND-1000 (Thermo Fischer  Scientific,
Waltham, USA) spectrophotometer that was blanked with either distilled water or DNA
rehydration solution, depending on what the DNA was dissolved in. The spectrophotometer
readings gave both a measure of DNA quality through the 260/280 and 260/230 ratios and
concentration. 
Cameroonian samples showed a mean concentration of 170 ng/μl (1,7 - 528 ng/μl), mean
260/280  ratio  of  1,8  (0,97  –  3,8)  and  mean  260/230  ratio  of  0,86  (0,03  -  1,94).  One
Cameroonian sample did not have a valid 260/230 reading. South African samples showed
a mean concentration of 642 ng/μl (54 – 1681 ng/μl), mean 260/280 of 1,86 (1,79 – 1,91)











Once  the  concentration  of  the  stock  DNA was  known,  each  sample  was  diluted  with
distilled water to give a working concentration of 100 ng/μl. If the stock concentration was
below 100 ng/μl then the DNA was kept at the original concentration and a portion of the
stock aliquoted into a working tube. The DNA dilutions were stored at 4 °C and used in all
further experiments while the stock DNA was stored at  -20  °C until  it  was needed for
further use.
Following dilution, 35-40 ng was run on a 1% agarose gel (LE agarose and 1X TBE) and
visualised with ethidium bromide under UV light. This was done to make sure that the
DNA was intact and there was no obvious contamination. Good quality DNA was observed
in most of the samples. Figure  9, below, is representative agarose gel electrophoresis of
working stock DNA. Samples were considered to pass the integrity check so long as they
displayed a single band at the top of the gel. None of the samples showed degraded DNA.
DNA was  subsequently  used  for  genotyping  for  variations  in  GJB2 and  GJA1,  using
primers  that  were  synthesised  at  the  Synthetic  DNA Laboratory  of  the  Department  of












4.3.2- Amplification Of GJB2
Amplification  of  the  GJB2 gene  was  performed  according  to  the  methods  of  Liu  et
al.53 Two primers were used to amplify a 900 bp region of the GJB2 gene which contained
the complete coding region of exon 2. The structure of GJB2 can be seen in Figure 10.
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Figure 9: An example of an integrity gel. All samples, including those not shown, have










The PCR mixture consisted of 1X GoTaq colourless buffer (Promega, Madison, USA), 200
μM  nucleotide  mix,  0,4  μM  of  each  primer,  0,5  U  of  GoTaq  Polymerase  (Promega,
Madison,  USA),  100  ng  of  DNA and  was  made  up  to  25  μl  with  distilled  water.
Amplification consisted of an initial denaturation step at 95 °C for 5 minutes, followed by
30 cycles  of denaturation at  95 °C for 1 minute,  annealing at  60 °C for 1 minute and
extension at 72 °C for 1 minute; followed by a final extension at 72 °C for 5 minutes.
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Figure 10: Structure of GJB2/CX26. From top to bottom the figure shows the position of
GJB2 on chromosome 13, the position of the two exons in GJB2 (labelled 1 and 2) and
the structure of the mRNA. The coding region falls completely within exon 2. (Source:










4.3.3- Amplification Of GJA1
Structurally,  GJA1 is very similar to  GJB2 with the entire coding region residing in the
second exon. The most noticeable difference between the two genes is their size, while the
coding region of GJB2 comprises 680 bp, that of GJA1 is 1148 bp, at least 400 bp longer.
There is an even greater difference in the size of their introns, 3180 bp versus 11 000 bp
respectively.  A 1348 bp fragment of  GJA1,  containing the complete coding region, was
amplified using primers and a method adapted from that of Huang et al.69 
As  only  minimal  details  were  provided  in  the  paper  it  was  necessary  to  perform  a
temperature gradient PCR to determine the optimum annealing temperature, Figure 11. This
was  performed  at  the  following  cycling  conditions  and  with  the  same  reagent
concentrations  as  described  in  section  4.3.2.  Amplification  consisted  of  an  initial
denaturation step at 95 °C for 2 minutes, followed by 30 cycles of denaturation at 95 °C for
30 seconds, an annealing temperature gradient of 56-62 °C for 30 seconds and an extension
at 72 °C for 1,5 minutes; followed by a final extension step at 72 °C for 5 minutes. Based












4.3.4- Sequencing Of GJB2 And GJA1
After amplification of the desired region, PCR products were genotyped by sequencing,
following  a  sequencing  protocol  that  included  PCR  clean-up,  sequencing  reaction,
sequencing clean-up and electrophoresis. PCR products were cleaned by mixing 5 μl of the
product  with  1  μl  of  FastAP Thermosensitive  Alkaline  Phosphatase  (Thermo  Fischer
Scientific, Waltham, USA), 0,1 μl Exonuclease I (Thermo Fischer Scientific (Fermentas),
Waltham, USA) and made to 20 μl final volume with distilled water.  The mixture was
incubated at 37 °C for one hour followed by 75 °C for 15 minutes.
After PCR clean-up, 3  μl of the cleaned product was combined with 2 μl 5X sequencing
buffer (Applied Biosystems, Foster City,  USA), 1 μl BigDye V3.1 Terminator (Applied
Biosystems, Foster City, USA), 1 μl either forward or reverse primer and made up to 10 μl
in distilled water. All samples were sequenced in both the forward and reverse direction
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Figure  11:  GJA1 temperature  gradient.  An  annealing
temperature  of  57 °C was chosen to  minimise non-specific










with the same primers used for amplification. Samples were run in a thermal cycler for 1
cycle of 5 minutes at 98 °C and either 30 (GJB2) or 35 (GJA1) cycles of denaturation for
30 seconds at 96 °C, annealing for 15 seconds at 50 °C and extension for 4 minutes at 60
°C.  After  the  sequencing  reaction,  samples  were  cleaned  by  ethanol  precipitation  as
described in Appendix I.VIII. 
After  the  sequencing  reaction,  electrophoresis  was  performed  in  96-well  plates  on  an
ABI3130XL Genetic Analyser (Applied Biosystems, Foster City, USA). Wells contained a
mixture  of  8  μl  Hi-Dye  formamide  and  5  μl  cleaned  sequencing  reaction.  GJB2 was
sequenced in both directions and overlapped over almost the complete length of the product
but, due to its length, we did not have forward and reverse strand overlaps for the majority
of  the  GJA1  coding  region.  However,  we  decided  this  was  a  minor  limitation  as  any
ambiguous results could be resequenced.
4.4- Bioinformatics And Statistical Analysis
4.4.1- Sequencing Quality-Check
Chromatogram files were manually checked using FinchTV 1.3.1 (GeoSpiza, Seattle, USA)
then aligned in BioEdit 7.0.5.3, running through WINE 1.4. Sequences were aligned to the
GJB2 reference sequence (Ensembl transcript ENST00000382848 (GJB2-001) retrieved 31
August 2012) or the  GJA1 reference sequence (ENSG00000152661, retrieved 13 March
2013).
4.4.2- Molecular Analysis
Detected  variations  were  checked  against  dbSNP90 and  the  effects  of  non-synonymous











to check for statistical differences between the cases and controls. SHEsis analysed allele
frequency,  genotype  frequency,  haplotype  frequency  and  linkage  disequilibrium.
Significance of SHEsis results is reported using Fischer's p-values.
4.4.3- Phylogeny  Construction  And  Principal  Components
Analysis (PCA)
SNP frequencies for the sequenced region of  GJB2 and  GJA1 was downloaded from the
1000  Genomes  Browser  (http://browser.1000genomes.org)  for  all  populations.94 A
phylogeny  was  then  constructed  with  PopTree  software  using  the  Neighbour  Joining
algorithm,  Nei's  DA genetic  distance95 and  1000  bootstraps.  PCA was  performed  in
R96 using  the  FactoMineR  package  with  the  same  1000  Genomes  data.  As  the  1000















One South African control, four Cameroonian controls and 12 Cameroonian patients were
excluded from the  study due  to  low DNA concentrations,  failure  to  amplify the  GJB2
coding region or failure when sequencing. This left our total number of participants for
GJB2 analysis at 25 South African patients, 16 South African controls, 180 Cameroonian
patients and 60 Cameroonian controls. A summary of the participants' sociodemographic
information can be seen in Table 2.
Table 2: Sociodemographics of GJB2 study participants.
Demographic
South Africa Cameroon
Case (Freq.) Control (Freq.) Case (Freq.) Control (Freq.)
Gender
Male 20 (0,80) 0 (0,00) 94 (0,52) 36 (0,60)
Female 4 (0,16) 6 (0,38) 84 (0,47) 24 (0,40)
Unknown 1 (0,04) 10 (0,63) 2 (0,01) 0 (0,00)
Age
Average 13,95 47,75 11,81 13,53




3 (0,12) NA 157 (0,87) NA
Perilingual 
(2-4 years)
6 (0,24) NA 0 (0,00) NA
Postlingual 
(>4 years)
3 (0,12) NA 14 (0,08) NA
Unknown 13 (0,52) NA 9 (0,05) NA
Transmission
Familial 5 (0,20) NA 47 (0,26) NA
Sporadic/unknown 20 (0,80) NA 133 (0,74) NA











Of the 47 familial cases (26,11%) in Cameroon, our analysis includes two cases of two
affected siblings, two cases of three affected siblings and one case of four affected siblings.
Consanguinity was not reported in the South African cohort but 10 (5,56%) Cameroonian
patients were from known consanguineous unions.
The majority of Cameroonian patients (70%) suffered from sensorineural hearing loss, a
small number (4,4%) suffered from mixed hearing loss and the type of hearing loss was not
determined for the remainder. Hearing loss was not symmetrical for all patients but was
always severe. Audiological information was not available for patients recruited from South
Africa. The breakdown by level of hearing loss per ear can be seen in Table 3.
Table 3: Breakdown of severity of hearing loss in Cameroonian patients genotyped
for GJB2. Level of deafness given according to BIAP classification.97
Severity of Deafness Left Ear (Frequency) Right Ear (Frequency)
Severe 1 (71-80) 6 (0,03) 7 (0,04)
Severe 2 (81-90) 19 (0,11) 20 (0,11)
Profound 1 (91-100) 53 (0,29) 54 (0,30)
Profound 2 (101-110) 49 (0,27) 46 (0,26)
Profound 3 (111-119) 17 (0,09) 22 (0,12)
Total (120) 7 (0,04) 2 (0,01)
Unknown 29 (0,16) 29 (0,16)
N=180 N=180
5.1.2- Molecular Analysis Of GJB2
Sequence variations were confirmed on both the forward and reverse strand. Once spurious
readings were eliminated, we were left with a total of 10 variations, both in the 5'UTR and
the coding region. The chromatogram results for all the variations are available in Figure 12











Table  4:  GJB2 variations detected in Cameroon and South Africa.  Domains:  IC =
Intracellular domain, EC = extracellular domain, TM = transmembrane domain.
Genomic Transcript Protein Domain RS number Pathogenicity
g.3318-41G>A c.-41G>A NA Intron Novel Polymorphism
g.3318-34C>T c.-34C>T NA Intron rs9578260 Polymorphism
g.3318-15C>T c.-15C>T NA 5'UTR rs72561725 Polymorphism
g.3318-6T>A c.-6T>A NA 5'UTR rs148136545 Polymorphism
g.3332G>A c.15G>A p.= IC1 Novel Polymorphism
g.3503C>T c.186C>T p.= EC1 Reported Polymorphism
g.3542G>T c.225G>T p.= EC1 rs149137695 Polymorphism
g.3741_3743delTTC c.424_426delTTC p.(F142del) TM3 Reported Pathogenic
g.3774G>A c.457G>A p.(V153I) TM3 rs111033186 Polymorphism
g.3816G>A c.499G>A p.(V167M) EC2 rs111033360 Possibly pathogenic
Sequencing  revealed  two  pathogenic  or  probably  pathogenic  mutations  in  Cameroon,
g.3741_3743delTTC (p.(F142del))  and  g.3816G>A (p.(V167M)).  Each  was  detected  in
only a  single individual  and both  in  the  heterozygous state.  There  were no pathogenic
mutations detected in South African patients.
A number of variations in the  GJB2 sequence in both Cameroonian and South African
patients  were  also  uncovered.  We  detected  two  novel  variations,  g.3318-41G>A and
g.3332G>A, both in the heterozygous form. g.3318-41G>A occurs in the first intron of
GJB2 and g.3332G>A is a synonymous variation. The most common variants in both South
African  and  Cameroonian  patients  were  the  intronic  change  g.3318-34C>T  and  two
changes in the 5'UTR, g.3318-15C>T and g.3318-6T>A.
There were no statistically significant  differences  between genotype  (Table  5)  or  allele












Figure  12:  GJB2 variations  detected in  Cameroon and South Africa. A =  g.3318-
41G>A (Novel), B= g.3318-34C>T, C= g.3318-15C>T, D= g.3318-6T>A, E = g.3332G>A
(Novel),  F  =  g.3503C>T,  G  =  g.3542G>T,  H  =  g.3741_3743delTTC (Pathogenic),  I  =















Table 5: GJB2 genotype frequencies in the South African and Cameroonian cohorts. Freq. = frequency.
Variant
South Africa Cameroon
























































































































































































Table 6: GJB2 minor allele frequencies in South African and Cameroonian cohorts. Freq. = frequency.
Variant Minor Allele South Africa Cameroon
Cases (Freq.) Controls (Freq.) P-value Cases (Freq.) Control (Freq.) P-value
g.3318-41G>A A 0 0 NA 1 (0,003) 0 0,563
g.3318-34C>T T 32 (0,364) 7 (0,219) 0,134 100 (0,278) 40 (0,333) 0,246
g.3318-15C>T T 13 (0,148) 1 (0,031) 0,079 15 (0,042) 7 (0,058) 0,450
g.3318-6T>A A 1 (0,011) 0 0,545 4 (0,011) 1 (0,008) 0,795
g.3332G>A A 0 0 NA 2 (0,006) 0 0,413
g.3503C>T T 0 0 NA 1 (0,003) 0 0,563
g.3542G>T T 0 0 NA 0 1 (0,008) 0,083
g.3741_3743delTTC delTTC 0 0 NA 1 (0,003) 0 0,563
g.3774G>A A 0 1 (0,031) 0,096 0 0 NA











There was no statistically significant difference between haplotypes in the Cameroonian
cohort (Table  7) but there was a statistically significant difference in the South African
cohort (P = 0,03) (Table 8).
Table  7:  Haplotype frequencies between cases and controls in the Cameroonian
Cohort. Freq. = frequency.
Haplotype Case (Freq.) Control (Freq.) P-Value
G C C A G C G 1 G 1,79 (0,005) 1,00 (0,008) 0,515
G C C T G C G 1 G 242,67 (0,674) 71,02 (0,592) 0,101
G C C T G C T 1 G 0 1,00 (0,008) 0,083
G C T T G C G 1 G 12,63 (0,035) 6,98 (0,058) 0,268
G T C T G C G 1 G 93,24 (0,259) 39,98 (0,333) 0,116
G T T T G C G 1 G 1,46 (0,004) 0,02 (0,000) 0,877
A C C T G C G 1 G 1,00 (0,003) 0 0,563
G C C T G T G 1 G 1,00 (0,003) 0 0,563
G C T A G C G 1 G 0,91 (0,003) 0 0,582
G T C A G C G 1 G 1,30 (0,004) 0 0,510
G T C T A C G 1 G 2,00 (0,006) 0 0,413
G T C T G C G 1 A 1,00 (0,003) 0 0,563
G T C T G C G 2 G 1,00 (0,003) 0 0,563
Global 0,594
Haplotypes  were  constructed  from the  following  SNPs:  g.3318-41G>A,  g.3318-34C>T,
g.3318-15C>T, g.3318-6T>A, g.3332G>A, g.3503C>T, g.3542G>T, g.3741_3743delTTC (1











Table  8: Haplotype frequencies between cases and controls in the South African
cohort.
Haplotype Case (Frequency) Control (Frequency) P-Value
C C T A 0 1,00 (0,031) 0,209
C C T G 24,00 (0,480) 24,00 (0,750) 0,016
T C T G 19,00 (0,380) 6,00 (0,188) 0,065
T T T G 0 1,00 (0,031) 0,297
C T A G 1,00 (0,020) 0 0,421
C T T G 6,00 (0,120) 0 0,042
Global 0,030
Haplotypes  were  constructed  from  the  following  SNPs:  g.3318-34C>T,  g.3318-15C>T,
g.3318-6T>A and g.3774G>A. Values that are statistically significant (P < 0,05) are in bold.
Linkage analysis results showed a low rate of recombination between markers but also that
they were uninformative of one another. This is can be explained by the low frequency of
most variants and the fact that they all appear within 600 bp of each other.
5.1.3- Phylogeny  Construction  And  Principal  Components
Analysis (PCA) Using Variation In GJB2
Phylogenetic  comparison  of  our  South  African  and  Cameroonian  data  and  the  1000
Genomes populations  showed samples  clustering into three clades,  representing Asians,












The first plane of the GJB2 PCA (Figure 14) contained only 40% of the variation between
population groups but does show that different populations are characterised by different
SNPs. African groups clustered in the bottom left section of the plot while Asians grouped
towards  the  right.  There  was  overlap  between  the  European  populations  and  admixed
populations which occurred at the centre and to the top left of the plot. A variable factor
map (Figure 15) was also generated, showing all the SNPs that were considered in the PCA
and the effect they had on the position in the PCA of the populations that contained them. 
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Figure 13: Phylogeny constructed from GJB2 SNP data. The three clades (from top to
bottom: Asian, African European) are clearly visible. Numbers indicate bootstrap values
over 1000 iterations. Population abbreviations are: ASW, Americans of African Ancestry in
SW USA; CEU, Utah Residents (CEPH); CHB, Han Chinese in Beijing; CHS, Southern
Han Chinese; CLM, Colombians from Medellin Colombia; FIN, Finnish in Finland; GBR,
British in England and Scotland; IBS, Iberian population in Spain; JPT, Japanese in Tokyo
Japan; LWK, Luhya in Webuye Kenya; MXL, Mexican Ancestry from Los Angeles USA;
PUR,  Puerto  Ricans  from  Puerto  Rico;  TSI,  Toscani  in  Italia;  YRI,  Yoruba  in  Ibadan











Figure  14: PCA of  study and 1000 Genomes Project populations with respect to
variation in GJB2. Population abbreviations are: ASW, Americans of African Ancestry in
SW USA; CEU, Utah Residents (CEPH); CHB, Han Chinese in Beijing; CHS, Southern
Han Chinese; CLM, Colombians from Medellin Colombia; FIN, Finnish in Finland; GBR,
British in England and Scotland; IBS, Iberian population in Spain; JPT, Japanese in Tokyo
Japan; LWK, Luhya in Webuye Kenya; MXL, Mexican Ancestry from Los Angeles USA;
PUR,  Puerto  Ricans  from  Puerto  Rico;  TSI,  Toscani  in  Italia;  YRI,  Yoruba  in  Ibadan











Figure 15: Contribution of SNPs to the GJB2 PCA. This plot shows how possession of











5.2- KID Syndrome In Two Cameroonian Patients
5.2.1- Clinical Presentation
Patient 1:
A five-year-old  girl  that  presented  with  a  profound,  bilateral,  sensorineural  deafness
diagnosed at two years of age. She was born at term to unrelated, healthy parents after an
uneventful pregnancy and normal vaginal delivery. She presented at birth with generalized
erythema and had a history of chronic otitis externa and hypohidrosis. Her psychomotor
development was normal, however physical examination revealed a generalized, thickened
skin and xeroderma, palmoplantar keratoderma and rippled hyperkeratotic plaques on the
knees and elbows . She had an aged facial appearance, hypotrichosis (sparse eyelashes and
eyebrows),  and  hyperkeratotic  lesions  in  the  external  auditory  canal.  Ophthalmologic
examination revealed a mild vascularizing keratitis which explained her photophobia and
reduced  visual  acuity.  Oral  examination  showed  dental  dysplasia  and  histopathological
examination of the skin revealed an acanthotic dyskeratosis. There was no family history of
a similar condition.
Patient 2:
A two-year-old  girl  that  presented  with  a  prelingual,  bilateral,  profound,  sensorineural
deafness. She was born at term after an uncomplicated pregnancy and delivery. Since two
months of age, she presented with thick, reddened patches of the skin that were dry and
scaly.  The thickness  of  the skin gradually increased as  she grew older.  At  the  time of
presentation at the health facility, physical examination revealed generalized ichthyosiform
erythrokeratoderma,  palmoplantar  keratoderma,  alopecia  universalis  and  atrichosis
(absence of eyelashes and eyebrows). Joint mobility of the elbows, knees and ankles was
significantly reduced by keratoderma. She had photophobia and ocular irritation and an
ophthalmologic examination revealed a vascularizing keratitis. The intraoral examination











parents and young sister were all healthy and there was no family history of similar clinical
presentation.
The two patients were unrelated with their  parents originating from, and living in, two
geographically distinct of area of Cameroon (Western and Centre provinces, about 400 km
apart).  Furthermore,  the  parents  belonged  to  two  different  ethno-linguistic  groups,  the
Bantu and Nilo-Sahelian respectively.
5.2.2- Molecular Characterisation Of KID Patients
Sequencing of the entire coding region of GJB2 in the two KID patients revealed, in both
patients, the presence of the c.148G>A (p.(D50N)) change (Figure 16). The same mutation
was  not  present  in  Cameroonian,  non-syndromic  deafness  individuals  or  in  60  healthy
persons of Cameroonian origin. While patient 1 presented only with this mutation, patient 2
was also heterozygous for the most-common variant, g.3318-34C>T. Even though there is
no  molecular  data  on  the  parents  of  these  two  KID  patients,  the  lack  of  clinical
manifestations  on  their  part  and  the  absence  of  proven  familial  cases  with  reduced












Figure  16:  Molecular  diagnosis  of  KID  syndrome.  Top  two  panels  are  from













For analysis of GJA1, where the evidence for a link between the gene and hearing loss is
weak, we chose a subset of the patients that we thought would give us the greatest chance
of detecting a link if one existed. We chose 100 patients which included six consanguineous
Cameroonian patients, 52 familial Cameroonian cases, five familial South African cases,
two Cameroonian patients with heterozygous GJB2 mutations, 15 prelingual Cameroonian
cases and the 20 remaining South African cases. All but four Cameroonian patients had
previously been genotyped for GJB2. The same control samples used for GJB2 were used
for GJA1. 
Samples were excluded if they failed amplify or sequence, leaving us with a final figure of
67 Cameroonian, 23 South African patients, 16 Cameroonian controls and 17 South African











Table 9: Sociodemographics of GJA1 study participants.










Male 19 (0,83) 0 (0,00) 35 (0,52) 8 (0,50)
Female 3 (0,13) 6 (0,38) 31 (0,46) 8 (0,50)
Unknown 1 (0,04) 10 (0,63) 1 (0,01) 0 (0,00)
Age
Average 14,4 47,75 12,12 14,31




2 (0,09) NA 63 (0,94) NA
Perilingual
(2-4 Years)
5 (0,22) NA 0 (0,00) NA
Postlingual
(>4 years)
3 (0,13) NA 3 (0,04) NA
Unknown 13 (0,57) NA 1 (0,01) NA
Transmission
Familial 5 (0,22) NA 47 (0,70) NA
Unknown 18 (0,78) NA 20 (0,30) NA
N=23 N=17 N=67 N=16
While there were no reported cases of consanguinity in the South African cohort,  nine
(13,43%) patients in the Cameroonian cohort were the result of consanguineous unions.
There were 57 (85,07%) patients with sensorineural,  one (1,49%) with mixed and nine












Table 10: Breakdown of severity of hearing loss in Cameroonian patients examined
for GJA1. Level of deafness given according to BIAP classification.
Severity of deafness Left Ear (Frequency) Right Ear (Frequency)
Severe 1 (71-80) 1 (0,01) 2 (0,03)
Severe 2 (81-90) 0 (0,00) 3 (0,04)
Profound 1 (91-100) 17 (0,25) 14 (0,21)
Profound 2 (101-110) 16 (0,24) 16 (0,24)
Profound 3 (111-119) 6 (0,09) 7 (0,10)
Total (120) 3 (0,04) 1 (0,01)
Unknown 19 (0,28) 18 (0,27)
N=67 N=67
5.3.2- Molecular Analysis Of GJA1
Genotyping for  GJA1 by sequencing resulted in the detection of five sequence variants
(Described in Table 11 and examples visible in Figure 17), none of which were pathogenic.
Of the five, four are known SNPs and one, g.11522T>C, is novel. Only g.11873G>A was
detected in more than one individual. The majority of the variations were detected in the
South  African  cohort  with  Cameroonians  only  presenting  with  g.11873G>A  and
g.11090A>G. 
Table  11:  GJA1 variations detected in Cameroon and South Africa.  Domains: EC =
extracellular domain, IC = intracellular domain.
Genomic Transcript Protein Domain RS number Pathogenicity
g.11090A>G c.-67A>G NA Intron rs189167598 Polymorphism
g.11345T>C c.189T>C p.= EC1 rs139688042 Polymorphism
g.11522T>C c.366T>C p.= IC2 Novel Polymorphism
g.11873G>A c.717G>A p.= IC3 rs57946868 Polymorphism











Comparison  of  allele,  genotype  and  haplotype  frequencies  showed  no  statistically
significant differences in either the Cameroonian or South African cohort (Tables 12, 13, 14
and 15). Just as with GJB2, there was very little information for linkage disequilibrium. In
both populations the D` values were essentially 1 but the r2 values were almost 0. 
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Figure 17: Chromatogram of GJA1 variations. A = g.11090A>G, B = g.11345T>C, C =












Table 12: GJA1 genotype frequencies in South African and Cameroonian cohorts. Freq. = frequency.
South Africa Cameroon







































































































Table 13: GJA1 minor allele frequencies in South African and Cameroonian cohorts. Freq. = frequency.
Variant Minor allele South Africa Cameroon
Case (Freq.) Control (Freq.) P-value Case (Freq.) Control (Freq.) P-value
g.11090A>G G 0 0 NA 2 (0,015) 0 0,487
g.11345T>C C 1 (0,022) 0 0,387 0 0 NA
g.11522T>C C 1 (0,022) 0 0,387 0 0 NA
g.11873G>A A 2 (0,043) 3 (0,088) 0,414 11 (0,082) 1 (0,031) 0,318











Table 14: Haplotype frequencies in patients and controls from Cameroon.
Haplotype Case (Frequency) Control (Frequency) P-Value
A A 11,00 (0,082) 1,00 (0,031) 0,318
G A 121,00 (0,903) 31,00 (0,969) 0,229
G G 2,00 (0,015) 0 0,487
Global 0,467
Haplotypes were constructed from the following SNPs: g.11090A>G and g.11873G>A.
Table 15: Haplotype frequencies in patients and controls from South Africa.
Haplotype Case (Frequency) Control (Frequency) P-Value
A T T C 2,00 (0,043) 3,00 (0,088) 0,414
G T T C 41,00 (0,891) 31,00 (0,912) 0,763
G C T C 1,00 (0,022) 0 0,387
G T C C 1,00 (0,022) 0 0,387
G T T T 1,00 (0,022) 0 0,387
Global 0,583
Haplotypes  were  constructed  from  the  following  SNPs:  g.11345T>C,  g.11522T>C,
g.11873G>A and g.11914C>T.
5.3.3- Phylogeny  Construction  And  Principal  Components
Analysis (PCA) Using Variation In GJA1
The  phylogeny  created  from  GJA1 (Figure  18)  does  not  show  the  same  structure  or
grouping as that of GJB2. Only the African populations form one of the expected clusters,
although  with  much  lower  bootstrap  values  than  in  the  GJB2 phylogeny.  There  is  a
predominantly Asian cluster but it also includes the admixed Puerto Rican population as











Principal Components Analysis (PCA), Figure  19, divided the samples in a manner that
explained 56% of the variation between populations. It was also more informative than the
phylogeny in distinguishing groups. The African populations form an almost straight line of
increasing prevalence of the g.11873G>A variant.  The Asian populations  form a single
group at the bottom of the PCA with no other populations in their region. The European and
admixed populations are not easily distinguishable, similar to what was observed in the
GJB2 PCA. 
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Figure 18: Phylogeny constructed with GJA1 SNP data. Numbers indicate bootstrap
values over 1000 iterations.  Population abbreviations are:ASW, Americans of  African
Ancestry in  SW USA; CEU, Utah Residents (CEPH);  CHB, Han Chinese in  Beijing;
CHS, Southern Han Chinese; CLM, Colombians from Medellin Colombia; FIN, Finnish in
Finland; GBR, British in England and Scotland; IBS, Iberian population in Spain; JPT,
Japanese in Tokyo Japan; LWK, Luhya in Webuye Kenya; MXL, Mexican Ancestry from
Los Angeles USA; PUR, Puerto Ricans from Puerto Rico; TSI, Toscani in Italia; YRI,











Figure  19: PCA of  study and 1000 Genomes Project populations with respect to
variation in  GJA1. Population abbreviations are:ASW, Americans of African Ancestry in
SW USA; CEU, Utah Residents (CEPH); CHB, Han Chinese in Beijing; CHS, Southern
Han Chinese; CLM, Colombians from Medellin Colombia; FIN, Finnish in Finland; GBR,
British in England and Scotland; IBS, Iberian population in Spain; JPT, Japanese in Tokyo
Japan; LWK, Luhya in Webuye Kenya; MXL, Mexican Ancestry from Los Angeles USA;
PUR,  Puerto  Ricans  from  Puerto  Rico;  TSI,  Toscani  in  Italia;  YRI,  Yoruba  in  Ibadan











Figure 20: Contribution of SNPs to the GJA1 PCA. This plot shows how possession of












6.1- Strengths Of The Study
This  comprehensive  report  on  the  significance  of  connexin  mutations  in  deafness  in
Africans offers a substantial contribution to the literature on the topic. Our inclusion of
Cameroonian  patients  is  of  major  importance as  Cameroon is  frequently referred to  as
"Africa  in  miniature,"  because  of  its  central  location  on  the  continent,  its  many
geographical and cultural attributes and the diversity of it's population (There are more than
200 distinct  local  languages  in  the country).  The country spans two main geographical
zones of almost equal size: the equatorial rain forest in the south and the tropical savannah
and the Sahel region in the north. At the genetic level, Cameroonian population diversity
mimics that of various ethno-linguistic groups in African populations88 and it is anticipated
that results from a carefully selected sample in this population could represent a snapshot of
many African populations. Furthermore, we include patients from the Xhosa population of
South Africa, a formerly unstudied population but an offshoot of the Bantu population that
migrated from areas around Cameroon.
This study reports the first molecular diagnosis of KID Syndrome due to p.(D50N) in GJB2
in sub-Saharan Africa and conduct the first analysis of GJA1 in an African population. Data
from  the  1000  Genomes  Project  is  used  to  derive  meaning  from  our  findings.  The
information presented here builds on previously published studies on connexins and their
effect on deafness in African patients and contributing novel findings that further enrich the
literature and influence clinical practice on the continent in terms of suitable genetic testing.
6.2- GJB2
GJB2 mutations  have  been  shown  to  explain  a  large  proportion  of  deafness  in  many
different population groups.45,47,54 With only two mutations detected, both in heterozygotes,











similar to other results  from African studies that have also reported low frequencies of
deafness-associated mutations in GJB2 (Table 16).
Both  mutations  detected  here  have  been  described  previously.  The  p.(F142del)
(g.3741_3743delTTC)  mutation  has  been  detected  and  associated  with  deafness  twice
before, in the heterozygous state in an Egyptian patient suffering from moderate hearing
loss98 and  in  four  Chinese  patients  with  non-syndromic  hearing  loss.99 p.(V167M)
(g.3816G>A) has been reported in three studies and is possibly exclusive to patients of
African ancestry. It has been detected in a heterozygous state in 4/406 (~1%) Kenyans with
prelingual, non-syndromic hearing loss,12 1/94 (~1%) African American controls55 and in
1/19  (~5%)  patients  from  a  predominantly  African  American  cohort  of  patients  with
congenital CMV infection and hearing loss, although the exact ethnicity of the individual
with the variant is not mentioned.100 
Gasmelseed et al.12 proposed a possible dominant mode of inheritance for the p.(V167M)
mutation but that does not fit with the results that have since become available, particularly
its detection in unaffected controls, which supports a recessive mode of inheritance. While
it may be pathogenic, it has not been reported in a homozygous form and predictive tools
give ambiguous results.  Polyphen-291 predicts  it  as  "possibly damaging with a score of
0,618 (sensitivity: 0,87; specificity: 0,91)" with HumDiv and "possibly damaging with a
score of 0,537 (sensitivity: 0,82; specificity: 0,82)" with HumVar. The Polyphen-2 score
ranges from 0 to 1 and represents the probability that the change is damaging.
Three common variants were detected in our cohort,  all of which have previously been
reported  at  high  frequencies  in  African  populations.  These  are  g.3318-34C>T,  g.3318-
15C>T and g.3318-6T>A,  which  occured  in  60%,  28% and  4% of  our  South  African
patients respectively and 47,22%, 8,3% and 2,22% of Cameroonian patients respectively.
Our results  are  similar  to  those  of  Kabahuma et  al.  where  g.3318-34C>T and g.3318-
15C>T were the only variants detected in 182 case and 63 control individuals from the











42.6% of patients and controls respectively and the g.3318-15C>T change in 21,4% and
35% of patients and controls respectively. Although also from South Africa, the study did
not include members of the Xhosa population. The same variants, including the g.3318-
6T>A change, were also among those detected in deaf individuals from both Kenya and
Sudan.12 They found the g.3318-34C>T and g.3318-15C>T changes in 12,73%, 6,45% of
patients  respectively.  The  g.3318-6T>A change  was  only  found  in  0,49%  of  Kenyan
patients.
These variants appear to be almost exclusive to those of African ancestry,  perhaps best
illustrated by Tang et  al.101 Looking at  Tang et  al.'s  control  data,  which is  stratified by
ethnicity,  we  can  see  the  g.3318-34C>T,  g.3318-15C>T  and  g.3318-6T>A  variants
occurring in 27,8%, 2,78% and 2,08% respectively of African Americans but just 3,29%,
1,97% and 0% of Hispanics and none of the three variants occurring in either Asians or
Caucasians. Tang et al. also found a lack of polymorphisms in the coding region of GJB2
among African Americans but a high prevalence of variations in the 3'UTR, an area we did
not genotype in this study.
There has been one previous stud  of GJB2 and hearing loss in Cameroon whose results are
partially supported by this study.102 Out of 67 deaf and 66 normal hearing controls, two
GJB2 variants,  the  c.186C>T change  (in  two  patients  and  one  control)  and  c.296insT
change (in one control) were detected. There was no mention of the variants we report here
at high frequencies but this discrepancy could be due to differences between the primer
sequences used for genotyping. An additional weakness of Trotta et al.'s study could be the
sampling of  all  participants  from a single school  in  the  North of  the  country,  whereas











PCA  offers  some  SNPs  that  appear  to  differentiate  our  cohorts,  and  other  African
populations included in the 1000 Genomes Project, from non-African populations (Figure
15). However, for some of these SNPs, the frequencies are too low, and are limited to just a
single population, to provide a reliable way of separating out the populations. The same
situation arises when the patient cohorts are included in the analysis as they contain many
low frequency, unique SNPs which then appear to distinguish African populations.  The
three SNPs that we found at a high prevalence (g.3318-34C>T, g.3318-15C>T and g.3318-
6T>A)  appear  to  be  the  most  important  and  reliable  way  of  distinguishing  African
populations.
Although  we see  a  statistically  significant  difference  in  haplotype  frequencies  between
cases and controls in South Africa, this result is likely due to the small sample size of our
South African cohort with no other results suggesting a difference between the two groups.
None of the variants seen in the South African cohort are known to be pathogenic, making
their  connection  to  deafness  unlikely.  We did  not  find  a  difference  between cases  and
controls in South Africa and Cameroon, probably pointing to the lesser role  that  GJB2
variations play in deafness in Africans when compared to other populations.
A detailed comparison of our findings and those from other African and African American
studies can be seen in Table 16. This table only includes specific data from deaf individuals,
although  variants  detected  in  controls  are  also  referred  to.  The  table  shows  that  most
variations  occur  at  very low frequencies  and the  major  variants  are  common to  South
Africa,  Cameroon, Kenya and Sudan. The three common variants were not  reported in
Ghana,  possibly  because  they  fell  outside  of  the  sequenced  region.  The  p.(R143W)
(c.427C>T) change, common in Ghana, has not been detected in other African populations
but has been seen in African Americans who could have originated from Ghana.
Our results are in agreement with other African studies, showing a unique African mutation
spectrum.  Studies  have  found  that  GJB2 mutations  are  detected  in  18% of  alleles  in











found GJB2 mutations in less than 1% of Cameroonian and 0% of South African alleles.
Similarly to Africans, Caribbean Hispanics do not show a large contribution to deafness
from  GJB2 variations.13 Neither  the  recessive  c.35delG  nor  c.235delC  variants  were
detected in the 1000 Genomes Project data, despite the c.35delG carrier frequency having
been  estimated  at  2%  in  European  populations  and  the  c.235delC  carrier  frequency
estimated at 1% in East Asian populations.105 This may be due to the fact that accurate
genotyping  of  small  insertions  and  deletions  with  next-generation  sequencing  remains
challenging.106
The difference between African and non-African populations is not merely limited to the
frequency of GJB2 variations but the identity of the changes themselves. Our results here
do not include the mutations that are common in other populations, in agreement with the
literature that states that they do not occur in Africa. An exception is Tunisia, on the North
coast of Africa, which has a high frequency of the c.35delG change.57,58,107 This is due to the
Tunisian population being predominantly Arab. The three common African SNPs described











Table 16: Comparison of results between selected studies of GJB2 and hearing loss in African populations.
Variation Country (Observed/Total alleles (%))
Genomic Coding Pathogenicity Cameroon Ghana59 Kenya/Sudan12 South Africa Tunisia African American
g.3318-3201G>A c.-3201G>A (IVS1+1G>A) Pathogenic 1/262 (0,4%)%
g.3318-41G>A c.-41G>A Polymorphism 1/360 (0,3%)*
g.3318-35T>G c.-35T>G Polymorphism 1/1178 (0,1%)
g.3318-34C>T c.-34C>T Polymorphism 100/360 (27,8%)* 85/1178 (7,2%) 19/50 (38,0%)*, 119/364
(32,7%)@
g.3318-15C>T c.-15C>T Polymorphism 15/360 (5,8%)* 38/1178 (3,2%) 7/50 (14,0%)*, 56/364 
(15,4%)@
1/46 (2,2%)+, NA+
g.3318-6T>A c.-6T>A Polymorphism 4/360 (1,1%)* 2/1178 (0,2%) 1/50 (2,0%)*
g.3332G>A c.15G>A Polymorphism 1/360 (0,3%)*
g.3352_3353insG c.35dupG Pathogenic 1/730 (0,1%)




g.3395C>T c.78C>T Polymorphism 1/1178 (0,1%)
g.3396C>T c.79G>A Pathogenic 2/46 (4,3%)+, NA+
g.3419T>C c.101T>C Pathogenic NA+
g.3426G>A c.109G>A Pathogenic 1/1178 (0,1%) 1/190 (0,5%)& 
2/262 (0,8%)%
g.3455_3460del c.138_143del Pathogenic 1/1178 (0,1%)
g.3456G>T c.139G>T Pathogenic 3/190 (1,6%)& 
8/262 (3,1%)%
g.3503C>T c.186C>T Polymorphism NA*, 2/122 (1,6%)# 3/1178 (0,3%)
g.3512C>A c.195C>A Pathogenic 1/1178 (0,1%)











Genomic Coding Pathogenicity Cameroon Ghana Kenya/Sudan South Africa Tunisia African American
c.3552delC c.235delC Pathogenic 2/262 (0,8%)%
g.3553T>C c.236T>C Pathogenic 1/730 (0,1%)
g.3566C>G c.249C>G Pathogenic 1/100 (1,0%)~
g.3586_3587insT c.269_270insT Pathogenic NA#
g.3627A>C c.310A>C Polymorphism 1/1178 (0,1%)
g.3650_3651delAA c.333_334delAA Pathogenic 2/190 (1,1%)&
g.3658A>G c.341A>G Pathogenic NA+
g.3697G>A c.380G>A Pathogenic 1/1178 (0,1%)
g.3706G>C c.389G>C Pathogenic 1/262 (0,4%)%
g.3741_3743delTTC c.424_426delTTC Pathogenic 1/360 (0,3%)*
g.3744C>T c.427C>T Pathogenic 110/730 (15,1%) 1/100 (1,0%)~
g.3774G>A c.457G>A Polymorphism 2/1178 (0,2%) NA*
g.3795G>A c.478G>A Pathogenic 1/1178 (0,1%) NA+
g.3816G>A c.499G>A Pathogenic 1/360 (0,3%)* 4/1178 (0,3%) NA+
g.3850T>C c.533T>C Pathogenic 4/730 (0,5%)
g.3868G>C c.551G>C Pathogenic 1/190 (0,5%)&
g.3868G>A c.551G>A Pathogenic 1/730 (0,1%)
g.3906G>T c.589G>T Pathogenic 1/730 (0,1%)
g.3925-3926delinsAA c.608_610delinsAA Pathogenic 2/730 (0,3%)
g.3958C>T c.641T>C Pathogenic 1/730 (0,1%)
Variant information was obtained through the relevant paper's own results and a combination of Deafness Variation Database108 and The
Connexin-Deafness Homepage.109 NA refers to variations that were found during the study but only in the control group. *This study, #Trotta












While KID syndrome has  been diagnosed in  African  patients  before,110 this  is  the first
observation of the p.(D50N) mutation in sub-Saharan Africa. Both patients are unrelated
and have no family history of skin conditions. The parents did not provide their own DNA
for comparison so we can not say for certain whether this is a  de novo mutation or not,
although it seems likely.
Our  confirmation  of  the  p.(D50N)  mutation  in  Cameroonians,  having  previously  been
observed  in  patients  of  European  ancestry,82,83 from  Egypt/Middle  East,111 South
Korea112 and Algeria,84 confirms that p.(D50N) is not linked to ethnicity. In contrast, GJB2
mutations causing non-syndromic hearing loss have been reported in many parts  of the
world  and  have  been  observed  to  have  marked  variations  in  their  frequencies  among
different ethnicities. This is  due to the major mutations in various groups being due to
population-specific founder effects,  as shown for c.35delG in Caucasians,9 c.167delT in












Of the five variants detected in GJA1, only one is a non-synonymous change and none are
known to be pathogenic. This means that these results do not allow us to assign a cause of
deafness to any of the patients. This result is not entirely unexpected and confirms what
other  studies  have  shown  while  expanding  the  range  of  populations  examined.  A
comparison of the variants discovered in all published studies on  GJA1 and deafness is
available in Table 17.
The p.(A253V) variant has been detected before in a Caucasian control allele,61 a Brazilian
patient with ichthyosiform erythrokeratodermia113 and both cases and controls in a study on
sudden infant deaths.68 It was also the only non-synonymous change found in the Iranian
study of  GJA1 and hearing loss.76 It is generally regarded as having little effect on the
protein and Polyphen2 predicts the variant to be "benign" with a score of 0,008 (sensitivity:
0,96; specificity: 0,76) using HumDiv and a score of 0,002 (sensitivity: 0,99; specificity:
0,18) using HumVar. While p.(A253V) does not appear to be linked to any disease, there is
evidence  that  it  may  act  as  a  modifier  of  disease  severity  in  Axenfeld-Rieger
syndrome114 and has been shown in vitro to result in a loss of tumour-suppressor activity.115
No mention of the other variants was found in a literature search, using Google Scholar
(http://scholar.google.co.za/) with "GJA1" and either either the RS number, coding change
description or protein change description as keywords. In addition no links to published
literature  were  available  on  their  respective  dbSNP  pages.  Both  g.11873G>A  and
g.11914C>T were present in our data as well as multiple populations in the 1000 Genomes
dataset.
The poor differentiation between population groups in both the phylogeny and, to a lesser
extent, the PCA is the result of a relative lack of variation in the  GJA1 gene. It's worth











because of the relatively large number of unique variants, albeit at such low frequencies
that they can be discounted. Not only did we find more variations in  GJB2, 10 in  GJB2
versus five in GJA1, but the number of patients with each GJB2 variant was higher than the
number  per  GJA1 variant..  This  is  also  despite  a  greater  region  being  sequenced  and
compared, 760 bp in GJB2 versus 1242 bp in GJA1. There were 29 different SNPs in the
1000 Genomes data for GJB2 but only six in the GJA1 data, with the Japanese population
reporting no changes. This lack of sequence diversity may be due to the wide expression
pattern of  GJA1, demonstrated by the variable phenotype of ODDD, which can include
skeletal abnormalities, dry skin, mental retardation and hearing loss,61,62,63 suggesting that











Table 17: Comparison of GJA1 variations in studies of GJA1 and deafness.
Variation Country (Observed/Total Alleles (%))
Genomic Transcript Protein Pathogenicity Cameroon* Iran# South Africa* Thailand Turkey@
g.11090A>G c.-67A>G NA Polymorphism 2/134 (1,5%)
g.11345T>C c.189T>C p.= Polymorphism 1/46 (2,2%)
g.11409G>C c.253G>C p.(L181F) Pathogenic 1/506 (0,2%)$
g.11522T>C c.366T>C p.= Polymorphism 1/46 (2,2%)
g.11780C>T c.624C>T p.= Polymorphism 1/520 (0,2%)%
g.11873G>A c.717G>A p.= Polymorphism 11/134 (8,2%) 1/68 (1,5%) 2/46 (4,3%) 1/520 (0,2%)%
g.11914C>T c.758C>T p.(A253V) Polymorphism 1/68 (1,5%) 1/46 (2,2%)
g.12132C>T c.976C>T p.(T326S) Unknown 2/520 (0,4%)%
g.12308_12309dupA c.3*_4*dupA NA Unknown 2/68 (3%)
Pathogenicity obtained from the study's description or prediction with Polyphen2. The p.(T326S) variant received conflicting predictions so
is classed as unknown. No variations were detected in Turkey in 120 chromosomes.  * = this study, # = Kooshavar et al.,76 $ = Yang et











6.5- Limitations Of Our Study
There are a number of limitations to the study that need to be acknowledged. Our methods
only  amplified  the  coding  region  of  GJB2 and  can  not  detect  non-coding  mutations
elsewhere in the gene which may affect transcription or mRNA stability.116 In addition, we
have classified newly identified SNPs as benign based on a combination of their location,
frequencies in patients and controls, whether the variant alters the amino acid and according
to predictive tools. It is possible that such a classification may incorrectly identify a variant
as benign either due to the low prevalence of the variant or as the variant may have a more
subtle effect, such as splicing or codon usage bias.
The South African cohort had a small sample size and this could have resulted in missing
variants that do not occur at high frequencies. Taking into account previous work in South
Africa  and  our  results  from Cameroon,  we  do  not  feel  that  this  is  particularly  likely.
Another limitation is the poor clinical description of the South African cohort included in
this study. Patients were not fully phenotyped and it is possible that some were included
inappropriately. Despite these limitations, the careful phenotyping and the diversity of the
Cameroonian samples, strongly validates our findings, particularly in the samples that were
used to investigate GJA1 mutations, where 70% of case were familial and likely genetic in
origin.
6.6- Practice Implications
Our results support the currently published literature and the hypothesis that mutations in
GJB2 are not a common cause of recessive, non-syndromic deafness in Africa. We add to
the literature by showing that mutations in GJA1 do not contribute to the genetic causes of
non-syndromic  hearing  loss  in  Africans.  Thus,  genetic  testing  for  these  two  genes  in











7- Perspectives And Research Recommendations
Our future work is focussed on investigating the genetic variation in  GJB6 (connexin 30)
because the large deletion, del(GJB6-D13S1830), in compound heterozygosity with GJB2
variants, has been shown to be the second most frequent cause of genetic deafness in some
European populations.117,118 Work is currently ongoing but provisional results do not show
del(GJB6-D13S1830) or sequence variations in the same 100 patient cohort as selected for
GJA1.  If  no mutations are found in  GJB6, the most efficient way to identify deafness-
causing mutations will by examining a large number of genes simultaneously through either
whole  genome  or  whole  exome  sequencing  (WES).  Indeed,  the  identification  of  the
causative  mutation  in  families  with  hearing  loss,  using  classical  single  gene  screening
approaches, is difficult and unaffordable as 65 different genes are known to be involved in
non-syndromic hearing loss.35 
WES provides unprecedented opportunities to identify causative DNA variants in many
families with hereditary diseases and has proven successful at  elucidating the causes of
deafness in a variety of genes and p pulations, even in small families.119,120,121,122,123,124 We
are fortunate to have enough samples and families to be able to combine homozygosity
mapping and WES in Cameroonian and South African families with autosomal recessive
non-syndromic  hearing  loss.  To  achieve  these  goals,  we  have  began  setting  up
collaborations with laboratories that are able to perform such high-throughput sequencing
using platforms like OtoSCOPE, which combines targeted genomic enrichment and next
generation sequencing to examine 66 deafness genes at once.120,125 We have also initiated a
pilot study to perform whole exome sequencing in a selected group of patients. Hopefully,
both approaches could help to unravel the genetic aetiology of hearing loss in some African
families.
Even with WES, the results will heavily depend on our cohort. While our Cameroonian











sociodemographic data and suffers from a small sample size. In future experiments it will
be necessary to recruit a larger cohort as well as collaborating with audiologists to generate
the  required  data.  Collaborations  with  other  researchers  will  also  allow recruitment  of
larger cohorts, more resources and the ability to recruit patients from countries where there












Our results show that neither  GJB2 (CX26) nor  GJA1 (CX43) is significantly associated
with non syndromic deafness in Africans. We have expanded the range of the KID-causing
p.(D50N)  mutation  in  two  Cameroonian  patients.  This  confirms  that,  contrary  to  non-
syndromic hearing loss, syndromic deafness due to GJB2 is not population-specific. These
finding  have  implications  in  clinical  practice  as  the  data  suggests  that  investigation  of
GJB2 (CX26)  and  GJA1 (CX43)  are  inappropriate  in  most  African  patients  with  non-
syndromic deafness.
Our results support the currently-published literature and the hypothesis that mutations in
GJB2 are not a common cause of recessive, non-syndromic deafness in Africa. This leaves
the genetic basis of deafness in Africans still unexplained. It is possible that deafness in
Africa is not caused primarily by a single gene but by small contributions from each of the
full  spectrum of  deafness  genes.  Future  studies  may benefit  more from whole genome
approaches, such as whole exome sequencing, as opposed to a single gene approach, to
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Date of inclusion …../…../…..  Place of Recruitment…………………Form  N-° ……..
I- IDENTIFICATION
Full name : ………………………………………………………………
Year of birth: ………. ………………..Sex : Male  1        Female  2   
Ethnicity: Xhosa 1              Other…………………
Grade at school: Efata school 1         Other………………….. 
Residence: ………………..   Contact number: …………………………….
II- CHARACTERISTICS OF DEAFNESS
Age of diagnosis of deafness: ………………………………..
Threshold of the tonal audiometry test: ……………………………………..
Bilateral:  Yes  1  No  2   Symmetrical  1     Asymmetrical 2
Mechanism: Sensorineural  1          Conductive  2          Mixed 3
Audiometric curve shape: …………………………….
Has the cause of deafness been established?     Yes  1    No  2   





Documented maternal infection : 











Potential terogens in during pregnancy:
 Aminoglycosides  1             Alcohol 2
b) Perinatal
Kernicterus  1                        Severe IUGR 2         Neonatal anoxia
 3  Obstetrical trauma 3                Teatment with aminoglycosides 4
GA at birth………WEEKS
c) Postnatal 
Recurrent Otitis media 1        Meningitis 2     Febrile convulsions 3
Mumps 2                         Measles  3                Mental retardation 4
Delay in walking  5         Blindness   6             Night-blindness 5
Severe myopia  6            Discomfort/fainting 7   Head trauma 8
Diabetes millitus 9          Diabetes insipidus 10    Hypothyroidy 12
Excessive urination/excessive thirst  13                    Hematuria 14
Hirschprung's disease  15       Kidney disease 16 specify……………..
2-Family History
     Deafness  1                          Kidney disease  2 specify
…………………..
     Diabetes melitus 3              White Forelock or white hair 4     Goiter
5
       
B- PHYSICAL EXAMANINATION
Facial dysmorphism 1                         Malformation of the external ear 2
Microcephaly  3                                   Leukocoria 4
Dystopia Canthaorum  5                      Microphthalmia 6
Residual cervical branchial 7               Vestibular ataxia 8
White hair and white eyebrows 9         Goiter 10















Yes  1    No  2   
Cervical ultrason
Yes  1    No  2   
Electrocardiogramme
Yes  1    No  2   
Opthalmological examination
Yes  1    No  2   
CT Brain
Yes  1    No  2   
Urine dipstick
Yes  1    No  2   
VI- MOLECULAR ANALYSIS











I.II- Consent Form (English)
1. I, ________________________________________________ , am consenting to 
provide my / my child's (DELETE WHERE NOT APPLICABLE) genetic material 
for a study on hearing loss in Black Africans.
Child's name (IF APPLICABLE):________________________________________
2. I understand that the genetic material for analysis is to be obtained from my / my 
child's (DELETE WHERE NOT APPLICABLE) blood cells. 
3. I request that no portion of the sample be stored for later use.  (MARK IF 
APPLICABLE )
 Or
I request that a portion of the sample be stored indefinitely for (DELETE WHERE 
NOT APPLICABLE):
( a ) possible re-analysis
( b ) analysis for the benefit of members of my immediate family
( c ) research purposes, subject to the approval of the University of Cape 
Town Research Ethics Committee, provided that any information from such 
research will remain confidential.
4. I authorise EFATA  to provide relevant clinical details to the Division of Human 
Genetics, UCT.
5. I understand that: 
( a ) there are benefits associated with genetic analysis and storage of biological 











( b ) the analysis procedure is specific to the genetic condition mentioned above 
and cannot determine the complete genetic make-up of an individual.
( c ) the genetics laboratory is under an obligation to respect medical 
confidentiality .
( d ) genetic analysis may not be informative for some families or family 
members.
( e ) even under the best conditions, current technology of this type is not perfect 
and could lead to incorrect results.
( f ) where biological material is used for research purposes, there may be no 
direct benefit to me.
6. I understand that I may withdraw my consent for any aspect of the above at any 
time without this affecting my future medical care.
7. When blood is drawn there will be someone available who can answer any 
questions I have in my own language.
Patient's signature or parent/guardian's signature if patient is under 18: 
_____________________________________
Witness of Consent: _____________________________________













I.III- Consent Form (Xhosa)
1. Mna,                                           , ndinika imvume yokuba kungathathwa imbewu 
yemfuzo efumaneka egazini kumntwana wam ukuze kufundwe ngesifo sokungeva 
kubantu abamnyama bese Afrika
Igama lomntwana:                                                                                          
2. Ndiyaqonda ukuba imbewu yemfuzo ezokuxilongwa izakuthathwa egazini 
lomntwana wam. ( CIMA APHO KUNGEKHO MFUNEKO)
3. Ndiyacela ukuba kungabikho ntsalela yesampule yegazi eyakuthi igcinwe umphelo 
 (YENZA UPHAWU UKUBA UFUNA OKU)
Okanye
Ndicela ukuba intsalela yesampule yegazi ingagcinwa umphelo ukuze
(a) Iphinde ixilongwe
(b) Ixilongwe ukwenzela inzuzo kumalungu osapho lwam ngqo.
(c) Injongo zophando, ngokunikwa imvume yi Komiti Yezophando nNgomntu 
yakwi Yunivesithi yase Kapa phantsi komqathango wokuba incukacha zabantu 
ezikoluphando zizohlala ziyimfihlo.
4. Ndinika imvume e EFATA ukuba inikise ngenkcukacha yesigulo kwi Ncandelo 
Lwezenzululwazi Ngemfuzo Ebantwini, e UCT.
5. Ndiyaqonda ukuba:
(a) Kukho inzuzo enxulumelene nokuxilongwa kwe mfuzo kunye nokugcinwa 











(b) Indlela yokuxilonga yeyesigulo sikhankanywe ngasentla qha futhi asikwazi 
ukubona yonke indlela imuzo yomntu eyenziwe ngayo.
(c) Indlu yemfuzo exilongayo inyanzelekile ukuba ihloniphe ukugcina 
inkcukacha zengulo yomntu ziyimfihlo.
(d) Uxilongo lwemfuzo kunga nganikiki lwazi lungaphaya kwamanye amakhaya
okanye kumalungu asekhaya.
(e) Nangona kusetyenzwa phantsi kwemeko ezingcono, izixhobo zalemihla
azigqibelelanga, sise okunika ingxelo ezingezizo.
(f) Apho kusetyenziswe khona igazi ngejongo zophando, kungangabikho nzuzo 
iqondene nam.
6. Ndiyaqonda ukuba ndingarhoxa kwisivumelwano nakowuphi umba ongasentla 
nangeliphi ixesha kwaye oko akusayi kuchaphazela isihoyo sempilo yam kwixa 
elizayo.
7. Xa kutsalwa igazi kuzakubakh  umntu ozokubakhona ukuphendula nawuphi 
umbuzo endinawo ngolwimi lwam.
Ukutyikitya komguli/ komzali/ ummeli womguli xa eneminyaka engaphantsi kwe 18
                                                                                                            











I.IV- Patient Information Sheet (English)
This study will be conducted by Jason Bosch for fulfilment of the requirements for an MSc
degree. The research will be supervised by Dr Ambroise Wonkam, Dr Collet Dandara and
Dr Karen Fieggen and performed at University of Cape Town in Department of Clinical
and Laboratory Services, Division of Human Genetics.
This  study  intends  to  increase  our  knowledge  of  the  genetics  of  non-syndromic
sensorineural  hearing  loss  in  Black  South  Africans  by examining  a  selection  of  genes
known to be involved in hearing loss. We will compare the information obtained to known
mutations and use family trees to determine what mutations are responsible for hearing loss
among Black South Africans.
We are performing this study as there is currently very little information on the genetics of
hearing loss  in  Black South Africans,  or  Africa as  a  whole.  This  is  important  because
hearing loss  has  many different  causes  which  are often  unique to  specific  populations.
Without the information that this study will provide we cannot know whether genetic tests
for  hearing  loss  are  appropriate  for  African  populations.  This  uncertainty  can  delay
assistance for those with hearing loss and could result in people spending money on tests
that are not suitable. 
The knowledge of which genes and mutations cause hearing loss will also be valuable in
providing counselling to parents both before they have children and about the probability of
having a second child with hearing loss.
There is no risk to anyone participating in the study as all that is needed is a blood sample











More information can obtained from Dr Nomlindo Makubalo who is assisting in patient
recruitment and the translation of all documentation into Xhosa.
• Dr Nomlindo Makubalo
Telephone: 021 406 6698 Email: np.makubalo@uct.ac.za 
Other  persons involved in  the  research can be contacted through the  UCT Division of
Human Genetics (Telephone: 021 406 6297) or by email.
• Jason Bosch
Email: jason.bosch@uct.ac.za 
• Dr Ambroise Wonkam
Email: ambroise.wonkam@uct.ac.za
• Dr Collet Dandara 
Email: collet.dandara@uct.ac.za 












I.V- Patient Information Sheet (Xhosa)
Olufundo luzakwenziwa ngu Jason Bosch ukuze abenako ukufezekisa izidingo zesidanga se
MSc.  Oluphando  luzakube  luphantsi  koqwalaselo  luka  Dr  Ambroise  Wonkam,  no  Dr
Collect Dandara kunye no Dr Karen Fieggen, futhi luzakuqhutyelwa kwiYunivesithi yase
Kapa kwi Sebe le Clinical and Laboratory Service kwiCandelo Lwezululwazi ngemfuzo
ebantwini.
Olufundo lunenjongo lokunyusa ulwazi ngemfuzo eyenza ukungeva ngeendlebe kubantu
abamnyama base Mzantsi Afrika ngokuthi kuxilongwe isixa sembewu yemfuzo eyaziwayo
ukuba  ngunobangela  wokungeva.  Siyakuthi  sifanise  ulwazi  olufunyenweyo  kutshintsho
lwembewu  kunye  neminombo  yamakhaya  ukuzama  ukufumana  eyona  mbewu
ingunobangela yo kungeva ngendlebe kubantu abamnyama base Mzantsi Afrika.
Senza olufundo ngokuba luncinci ulwazi lwembewu yemfuzo eyenza ukungeva ngendlebe
ebantwini abamnyama base Mzantsi Afrika, ne Afrika jikelele. Oku kubalulekile ngokuba
zininzi izinto ezingunobangela wokubasisithulu kwaye zahlukile ngokwengingqi yokuhlala.
Ngaphandle kokuthi  senze olufundo angeke siyazi  ukuba uxilongo lwembewu yemfuzo
olusetyenziswayo  lufanele  na  ukusetyenziswa  Kubantu  base  Afrika.  Oku  kuthandabuza
kungatsalelisa  emva  uncedo  lwabo  bazizithulu  futhi  lwenze  uchitho  mali  kwindlela
zokuvavanya  indlebe  ezingezizo.  Ulwazi  lwemfuzo  notshintsho  olungunobangela
lokungeva ngendlebe lungaluncedo kakhulu ekunikeni ingcebiso kubazali phambi kokuba
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I.VI- Dna Extraction From Blood
1. When fresh blood arrives and the volume is 3 ml or less,  transfer into a 15 ml
conical tube. If fresh blood is more than 3 ml, make a buffy and take 3 ml into the
15 ml conical tube.
2. Add 9 ml of filter-sterilised Red Blood Cell (RBC) lysis buffer, Mix well and leave
at room temperature for 30 minutes. Vortex briefly every 5 minutes or leave tubes
on a roller.
3. Vortex then centrifuge for 10 minutes at 2000 rpm.
4. Decant supernatant, add 1 ml of fresh RBC lysis buffer and mix by vortexing to
break up and mix the pellet so that it is smooth. (Repeat steps 3 and 4 for cleaner
pellet.)
5. Add 3 ml of filter-sterilised cell lysis buffer and mix well with vortex.
6. After mixing all of the samples, add 12,5 μl of 20 mg/ml Proteinase K and 100 μl of
20% SDS to each tube. Mix well with vortex.
7. Place tubes in 37 °C water bath for 1-3 days.
8. After incubation the liquid should be relatively clear with no pellet before moving
to the next step.
9. Mix with 1 ml of 6 M (saturated) NaCl and vortex vigorously.
10. Centrifuge at 2000 rpm for 20 minutes. (Repeat if supernatant is still turbid.)
11. Transfer the 5 ml supernatant to a clean 15 ml tube. Avoid touching the salt-protein
deposit at the bottom of the tube.
12. Add 2X the volume (10 ml) of 100% ethanol and mix gently, either by inverting
50X or using a roller for 5-10 minutes. Centrifuge at 2000 rpm for 10 minutes.
13. Decant supernatant and add 2 ml ice-cold 70% ethanol and centrifuge at 2000 rpm











14. Air dry the pellet for at least 2 hours at room temperature.
15. Reconstitute  DNA pellet  in  150  μl  DNA Rehydration  solution.  Leave  at  room
temperature  for  one  week  to  ensure  complete  reconstitution.  (If  not  completely
reconstituted place in 37 °C water bath and vortex occasionally.)
• Red Blood Cell Lysis Buffer (RBC Lysis Buffer)
• NH4Cl (Ammonium chloride): 8,82 g
• NH4HCO3 (Ammounium bicarbonate powder): 0,79 g
• EDTA (0,5 M, pH 7,4): 0,2 ml
• Make up volume to 1 l with ddH2O
• Filter sterilise with 0,2 μM micropore filter
• DNA Lysis Buffer/Cell Lysis Buffer
• Tris-HCl (1 M, pH 7,5): 25 ml
• NaCl (3 M): 16,7 ml
• EDTA (0,5 M): 1 ml
• Make up volume to 500 ml with ddH20 (Sterile water)
Excess blood was stored in the form of a buffy coat:
1. Centrifuge blood sample for 10 minutes at 2000 rpm. 
2. Transfer  1  ml  of  buffy coat  (all  leucocytes  and a  little  of  the  erythrocytes  and
plasma) into a 1,5 ml microcentrifuge tube.
3. Centrifuge for 10 minutes at 3000 rpm then store at -4 °C until storage box is full.











I.VII- DNA Extraction From Saliva
1. Mix the Oragene DNA/Saliva sample in the Oragene vial by inversion and gentle
shaking for a few seconds.
2. Incubate the sample at 50 °C in a water bath for a minimum of 1 hour or in an air
incubator for a minimum of 2 hours.
3. Transfer 1 ml of the mixed Oragene DNA/saliva sample in a 1,5 ml microcentrifuge
tube.
4. For  1 ml of  Oragene DNA/saliva,  add 40  μl  (1/25th volume) of  Oragene DNA
Purifier  (OG-L2)  to  the  microcentrifuge  tube  and  mix  by  vortexing  for  a  few
seconds.
5. Incubate on ice for 10 minutes.
6. Centrifuge at room temperature for 5 minutes at 13 000 rpm (15 000X g).
7. Carefully  transfer  the  clear  supernatant  with  a  pipette  tip  into  a  fresh
microcentrifuge tube. Discard the pellet containing the impurities.
8. To 750  μl of supernatant, add 500  μl of room temperature 95-100% ethanol. Mix
gently by inversion 10 times.
9. Allow the sample to stand at room temperature for 10 minutes to allow the DNA to
fully precipitate.
10. Place the tube in the microcentrifuge in a known orientation. Centrifuge at room
temperature for 2 minutes at 13 000 rpm (15 000X g). 
11. Carefully remove supernatant with a pipette tip ad discard it.  Take care to avoid
disturbing the DNA pellet.
12. Ethanol wash step. Carefully add 500  μl  of chilled 70% ethanol. Centrifuge for 1
minute at 13 000 rpm. Carefully remove the ethanol without disturbing the pellet.
13. Air-dry the pellet overnight.












1. Add the  following to  a  1,5 ml  microcentrifuge  tube;  22  μl  of  ice-cold absolute
ethanol, 1 μl 5M NaOAc pH 5 and 10 μl of sequencing reaction. 
2. Store the tubes at -20 °C for at least one hour or overnight.
3. Centrifuge at 10 000 rpm for 9 minutes.
4. Decant the supernatant and blot the tube on a paper towel.
5. Add 50 μl ethanol to the tubes, vortex and centrifuge at 10 000 rpm for 9 minutes.
6. Decant supernatant, blot dry and leave tubes to air dry for at least 30 minutes but
longer is better.











I.IX- Minor allele frequency of GJB2 SNPs available from the 1000 Genomes Project data
SNP ASW CEU CHB CHS CLM FIN GBR IBS JPT LWK MXL PUR TSI YRI
rs111033327 0 0 0 0 0,008 0 0 0 0 0 0 0 0 0
rs111033294 0 0 0 0 0,008 0 0 0 0 0 0 0 0 0
rs76838169 0 0 0,052 0,065 0 0 0 0 0,051 0 0 0 0 0
rs201004645 0 0 0 0 0 0 0,011 0 0 0 0 0 0 0
rs200104362 0 0 0 0 0 0 0 0 0 0 0 0,018 0 0
rs111033360 0 0 0 0 0 0 0 0 0 0,005 0 0 0 0
rs111033186 0 0 0 0 0 0 0 0 0 0 0 0 0,020 0
rs80338948 0 0 0 0 0 0,005 0 0 0 0 0 0 0 0
rs116769964 0 0 0 0 0 0 0 0 0 0 0 0 0 0,006
rs76434661 0 0,006 0,005 0 0 0 0 0 0 0 0 0 0 0
rs111033196 0 0 0 0 0 0 0,006 0 0 0 0 0 0,020 0
rs111033188 0 0 0,010 0,015 0 0 0 0 0,006 0 0 0 0 0
rs150529554 0 0 0 0 0 0 0,006 0 0 0 0 0 0 0
rs2274083 0 0 0,253 0,195 0 0 0 0 0,152 0 0 0 0 0
rs201839979 0 0 0 0,005 0 0 0 0 0 0 0 0 0 0
13:20763463 0 0 0 0 0 0 0,006 0 0 0 0 0 0 0
rs111033218 0 0,006 0 0 0 0 0,006 0 0 0 0 0 0,005 0













SNP ASW CEU CHB CHS CLM FIN GBR IBS JPT LWK MXL PUR TSI YRI
rs72474224 0 0 0,041 0,065 0,008 0 0 0 0,011 0,005 0,008 0 0 0
rs35887622 0,016 0,024 0 0 0,008 0,027 0,022 0 0 0 0,008 0,018 0,010 0
rs2274084 0,025 0 0,351 0,28 0,075 0 0 0 0,393 0 0,136 0,018 0 0
rs104894408 0 0 0 0 0 0 0 0 0 0 0,015 0 0 0
rs111033222 0,008 0 0 0 0 0 0 0 0 0 0 0 0 0
rs148136545 0,016 0 0 0 0,008 0 0 0 0 0,036 0 0 0 0
rs72561725 0,049 0,006 0 0 0 0 0 0 0 0,088 0,008 0,009 0 0,125
rs201895089 0 0 0 0 0 0 0,006 0 0 0 0 0 0,005 0
rs141962118 0 0 0 0 0 0 0 0 0 0 0 0 0,005 0
rs9578260 0,213 0 0 0 0,033 0 0 0 0 0,253 0,008 0,036 0 0,233













I.X- Minor allele frequency of GJA1 SNPs available from the 1000 Genomes Project data
Name ASW CEU CHB CHS CLM FIN GBR IBS JPT LWK MXL PUR TSI YRI
rs56199702 0 0,012 0 0 0,008 0,005 0,006 0 0 0 0,008 0 0 0
rs72548741 0 0 0 0,005 0 0 0 0 0 0 0 0 0 0
rs148384161 0 0,006 0 0 0 0 0 0 0 0 0 0 0 0
rs57946868 0,066 0,012 0,005 0 0,033 0,011 0,011 0,071 0 0,082 0,008 0 0,020 0,057
rs17653265 0 0,006 0 0 0,017 0 0,017 0,036 0 0 0,015 0,009 0,015 0
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Keratitis-Ichthyosis-Deafness (KID) syndrome (OMIM 148210) is a congenital ectodermal
defect that consists of an atypical ichthyosiform erythroderma associated with congenital
sensorineural deafness. KID appears to be genetically heterogeneous and most cases are
caused by GJB2 mutations. Mutations in African patients have been rarely described. 
Case presentation
We  report  on  two  unrelated  Cameroonian  individuals  affected  with  sporadic  KID,
presenting with the classic phenotypic triad. The two patients were heterozygous for the
most frequent p.Asp50Asn mutation. This first report in patients from sub-Saharan African
origin supports the hypothesis that the occurrence of KID due to p.Asp50Asn mutation in
GJB2 seems not to be population specific. 
Conclusions
Our  finding  has  implication  in  medical  genetic  practice,  specifically  in  the  molecular
diagnosis of KID in Africans. These cases also reveal and emphasize the urgent need to
develop appropriate policies to care for patients with rare/orphan diseases in Sub-Saharan
Africa, as many of these cases become more and more recognizable. 
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The Keratitis-ichthyosis-deafness (KID) syndrome (OMIM 148210 and 242150) is a rare
congenital  ectodermal  disorder  of  unknown prevalence.  Approximately  100 cases  have
been reported in the world to date [1]. KID appears to be genetically heterogeneous and
most  cases  are  caused  by  mutations  in  the  connexin  26  gene,  GJB2.  Connexins  are
membrane proteins with a common structure consisting of four transmembrane domains
linked  by  one  cytoplasmic  and  two  extracellular  loops  (namely,  EC1,  and  EC2,
respectively), with both cytoplasmic N-terminal and C-terminal [2]. Different mutations in
the  genes  encoding  connexins  can  disturb  the  gap  junction  system  of  one  or  several
ectodermal epithelia, which in the case in KID syndrome, where the epidermis, the inner
ear and the corneal epithelium are affected [3]. 
Skinner et al. reviewed 18 affected patients and proposed the acronym ‘KID syndrome’ to
describe  three  main  symptoms,  ichthyosis,  vascularizing  keratitis,  and  often  profound
sensorineural hearing loss [4]. KID is genetically heterogeneous and is caused by missense
mutations  in  the  connexin  (CX) genes  GJB2 and  GJB6,  which  cluster  at  chromosome
13q11-q12 and encode the closely related gap junction β-2 protein (coded by CX26) and β-
6 protein (coded by CX30) [5,6].  Inheritance of KID syndrome is  usually sporadic but
autosomal recessive and dominant cases have been reported [5]. 
Mutations  in  cases  of  KID syndrome have  been  rarely reported  in  patients  of  African
descent [7], but p.Asp50Asn mutation in the GJB2 gene have been previously only reported
in  a  black  patie t  from  the  Emirates  [8].  In  this  article,  we  report  on  two  unrelated
Cameroonian  patients  with  KID  syndrome  presenting  with  heterozygous  p.Asp50Asn
mutation in the GJB2 gene. 
Case presentation
Patients and methods
We  previously  published  on  aetiological  factors  of  congenital  hearing  loss  on  582












DNA amplification and mutation analysis
Genomic DNA samples were extracted from peripheral blood of the two patients, using
Puregene blood Kit® (Qiagen, USA), following the manufacturer’s protocol and this was
carried out in the Molecular Diagnosis Laboratory of the Gyneco-Obstetric and Paediatric
Hospital of Yaoundé, Cameroon. The  GJB2 gene was amplified following the method of
Liu et al. [10]. Exon 2 was amplified and then sequenced using an ABI 3130XL Genetic
Analyze® automated sequencer (Applied Biosystems, USA), in the Molecular Research
laboratory in the Division of Human Genetics, University of Cape Town, South Africa. 
Clinical data
Patient 1
A  five-year-old  girl  that  presented  with  a  profound  bilateral  sensorineural  deafness
diagnosed  at  2 years  old.  She  was  born  at  term  to  unrelated  healthy  parents  after  an
uneventful pregnancy and normal vaginal delivery, and presented at birth with generalized
erythema. She had a history of chronic otitis externa and hypohidrosis. Her psychomotor
development was normal; however, physical examination revealed a generalized thickened
skin and xeroderma, palmoplantar keratoderma and rippled hyperkeratotic plaques on the
knees and elbows (Figure 1A-D). She had aged facial appearance, hypotrichosis (sparse of
eyelashes  and  eyebrows),  and  hyperkeratosis  lesions  in  the  external  auditory  canal.
Ophthalmologic examination revealed a mild vascularizing keratitis which explained her
photophobia  and reduced  visual  acuity.  Oral  examination  showed  dental  dysplasia  and
histopathological examination of the skin revealed an acanthotic dyskeratosis. The parents











Figure 1. Illustrations of some clinical features of
the two Cameroonian KID cases (Case 1; panels A-
D; Case 2 panels E and F). A) Keratoderma of the
soles B) Rippled hyperkeratotic plaques on the knees;
C) Hypotrichosis of the eyelashes and eyebrows;  D)
Mild vascularizing keratitis; E) Hyperkeratosis of the
hands;  F) Alopecia,  hypotrichosis,  ichthyosiform
erythrokeratoderma. 
Patient 2
A two-year-old  girl  that  presented  with  a  prelingual  bilateral  profound  sensorineural
deafness. She was born at term after an uncomplicated pregnancy and delivery. Since two
months of age, she presented with thick, reddened patches of the skin that were dry and
scaly.  The thickness  of  the skin gradually increased as  she grew older.  At  the  time of
presentation at the health facility physical examination revealed generalized ichthyosiform
erythrokeratoderma,  palmoplantar  keratoderma,  alopecia  universalis  and  atrichosis
(absence of eyelashes and eyebrows) (Figure 1E-F). Joint mobility of the elbows, knees and
ankles was seriously reduced by keratoderma. She had photophobia and ocular irritation,
and  an  ophthalmologic  examination  revealed  a  vascularizing  keratitis.  The  intraoral
examination  was  normal.  She  had  no  major  neurological  abnormalities  and  her  non-
consanguineous parents and young sister were all healthy and there was no family history
of similar clinical presentation. 
On familial history, the two patients were unrelated: their parents originated from, and live
in, two geographically distinct of area of Cameroon (Western and Centre provinces, about













Analysis of  GJB2 exon 2 in the genomic DNA of the two unrelated patients revealed a
heterozygous missense  mutation  c.148G > A,  resulting  in  a  putative  amino acid change
from  aspartic  acid  (GAC)  to  asparagine  (AAC)  in  codon  50  p.Asp50Asn  (Figure 2).
p.Asp50Asn were not present in more than 180 unrelated individuals who were screened
for recessive deafness mutations or in 60 healthy control persons of Cameroonian origin
[unpublished results]. 
Figure  2. Mutation  analysis  of  GJB2 in  the  two
Cameroonian individuals affected with sporadic KID.
Panel  A:  Sequence  chromatograms  of  GJB2 from
unaffected individual; Panel  B: Sequence chromatograms
from  affected  patients  depicting  the  heterozygous
transition  148G → A at  codon  50  encoding  asparagine
instead of aspartic acid (p.Asp50Asn) (Panel B). 
Moreover, sequences data from both patients did not show any other common changes, but
the p.Asp50Asn variant. The DNA sequence in patient 1 did not have any other changes
than the p.Asp50Asn variant, while patient 2 was also heterozygote for the most common
non  pathogenic  polymorphism,  g.3318-34C > T.  Thus,  there  was  no  further  need  to
compare the haplotypes from the two patients to establish unrelatedness. 
Discussion
To the best of our knowledge, this is the first report of sub-Saharan African patients with
KID syndrome due to the p.Asp50Asn mutation in GJB2.
GJB2 mutations responsible for non-syndromic hearing loss have been reported in many
parts of the world with marked variations in distribution patterns among different ethnic
groups, with a propensity to occur frequently in some population groups (in Europe, North











GJB2 mutations causing autosomal recessive non-syndromic hearing loss (HL) which are
ethnically specific because of founder effect in some specific populations, GJB2 mutations
responsible for syndromic hearing loss seem not to be population specific [5]. 
The two patients reported here presented with the classic phenotypic triad of KID syndrome
including  diffuse  hyperkeratotic  erythroderma,  vascularizing  keratitis,  and  profound
bilateral  sensorineural  hearing  loss.  Several  other  features  were  associated  including
alopecia,  hypotrichosis  and  hypohydrosis,  porokeratotic  eccrine  ostial  and  dermal  duct
nevus, follicular occlusion triad and dental  anomalies previously [13,14]. Moreover, the
p.Asp50Asn  mutation  has  also  been  reported  in  KID  patients  with  Dandy-Walker
malformation [15];  although brain imaging was not performed, the two cases described
here did not have neurologic features that would suggest the occurrence of Dandy-Walker
malformation. The p.Asp50Asn mutation has been reported mostly in sporadic cases, but
also in a case of autosomal dominant inheritance [5]. In a cohort of 14 patients affected
with KID syndrome originating from 11 families, where parent to child transmission in
families was verified by molecular analysis, twelve patients (86%) were heterozygous for
the p.Asp50Asn mutation. The disease was sporadic in 64%, whereas 36% was familial,
suggestive of autosomal dominant inheritance with one parent clinically affected in all the
families. A family with p.Asp50Asn mutation was suggestive of germinal mosaicism, as the
parent was clinically normal [16]. Similar report of germinal mosaicism was also reported
in family with dizygotic twins suffering from a lethal form of KID; the two patients were
heterozygous for the p.G45E mutation of GJB2, whereas the mutation was not detected in
the  two  parents  [7].  The  two  pairs  of  Cameroonian  parents  did  not  consent  for  their
molecular  analysis,  claiming  in  both  cases,  that  this  will  not  have  any  implication  in
improving the care of their KID-affected children. However, since none of the parents were
clinically affected, and in absence of reported proven familial case with reduce penetrance,
mutations in these two Cameroonian cases are most likely de novo. 
p.Asp50Asn  appears  to  be  the  most  prevalent  mutation  in  unrelated  KID  patients  of
Caucasian ancestry [5,16], and the two unrelated Cameroonian cases provide additional











acid  replacement,  in  p.Asp50Asn  mutation,  occurs  in  the  highly  conserved  first
extracellular loop of CX26, which is crucial  for voltage gating and connexon-connexon
interactions [2,17]. The majority of dominantly-acting connexin mutations, associated with
autosomal dominant syndromic HL are situated in this domain and are missense mutations,
while the majority that cause recessive HL are nonsense mutations or small deletions [17].
Moreover, it has been observed that alteration of calcium ion fluxes due to the effects of
mutations  such as  p.Asp50Asn,  result  in cell  death by necrosis  [18].  In  addition,  other
functional analyses showed that p.Asp50Asn have consequences for protein localization
and gap junction permeability [19]. However, more evidences are needed to associate the
variable phenotypes observed in KID with effects on protein trafficking or gap junction
permeability. 
The management of KID syndrome in Cameroon as in other low-income countries is a
critical issue. The most beneficial treatment for the profound hearing impairment in our
patients could be cochlear implantation [20], a procedure that is unavailable in Cameroon.
There  is  no  universal  medical  insurance  in  Cameroon  and  even  hearing  aids  are  not
affordable  for  most  patients.  Keratitis  (also  observed  in  the  two  cases)  can  result  in
progressive decline of visual acuity and may eventually lead to blindness which combined
with  a  profound  hearing  loss  constitute  a  disastrous  disability.  In  addition,  a  life-long
follow-up of  these  patients  is  necessary because  the  KID syndrome is  associated  with
malignant tumours, particularly squamous cell carcinoma [1]. Although the provision of
service for medical care for KID patients is limited in Cameroon, better awareness of the
disease within the region would help patients if upon diagnosis, better prevention of the
worst effects of disease can be instituted, which besides follow-up for cancerous lesions,
would include simple preventative measures against fatal septicemia from recurrent skin
infections; specifically for the keratitis; there is a need to develop an appropriate specialist












In conclusion, our report supports the occurrence of KID due to p.Asp50Asn mutations in
GJB2 in Africans and seems to indicate that this mutation is not ethically specific. These
cases  reveal  and emphasize the urgent  need to develop appropriate  policies  to  care for
patients with rare/orphan diseases in Sub-Saharan Africa, as many of these cases become
more and more recognizable. 
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Background: Mutations in the GJB2 gene, encoding connexin 26, could account for 50%
of  congenital,  non-syndromic,  recessive  deafness  cases  in  some  Caucasian/Asian
populations. There is a scarcity of published data in sub-Saharan Africans.
Methods: We Sanger sequenced the coding region of the GJB2 gene, in 205 Cameroonian
and Black South African patients with congenital, non-syndromic deafness; and performed
bioinformatic analysis of variations in the  GJB2 gene, incorporating data from the 1000
Genomes Project.
Results: Amongst  Cameroonian  patients,  26.1%  were  familial  and  5.6%  were
consanguineous. The majority of patients (70%) suffered from sensorineural hearing loss.
Ten GJB2 genetic variants were detected by sequencing. A previously reported pathogenic
mutation,  g.3741_3743delTTC  (p.F142del),  and  a  putative  pathogenic  mutation,
g.3816G>A (p.V167M), were identified in single heterozygous samples. Amongst eight the
remaining  variants,  two novel  variants,  g.3318-41G>A and  g.3332G>A,  were  reported.
There were no statistically significant differences in allele frequencies between cases and
controls.
On a phylogenetic tree, Cameroonian and South African controls cluster with other African
populations. Principal Components Analyses differentiated between Africans, Asians and
Europeans but only explained 40% of the variation. 
Conclusion: Mutations in  GJB2 do not  play a major role  in  congenital  non-syndromic
genetic deafness in Africans.













Deafness is a global problem that is most serious in the developing world, with 7 per 1000
children in Nigeria born with deafness and 5.5 per 1000 live births in South Africa  1,  2.
These incidences are about five times higher than observed in the United States and Europe
3, 4.
Deafness is a highly complex condition caused by both genetic and environmental factors
as well as a combination of the two 5.Estimates for the aetiology of permanent childhood
deafness  in  the  US  and  Europe  are  approximately  20-30%  genetic,  another  20-30%
acquired  and  40-55%  unknown  3,  6..These  proportions  have  changed  over  time  with
improved healthcare reducing the number from infectious diseases, increasing the number
due causes such as prematurity and improving the detection of genetic causes. There is a
scarcity of data on the aetiology of hearing loss in Africa but recent work in Cameroon
shows the causes to be 15% genetic, 52% acquired and 33% unknown 7.
Deafness is non-syndromic,  when hearing loss is the only feature, or syndromic,  where
hearing loss is accompanied by other clinical features. Syndromic hearing loss is made up
of  more  than  400  different  syndromes  and  the  Hereditary  Hearing  Loss  Homepage
(http://hereditaryhearingloss.org/) lists 65 genes reported to be involved in non-syndromic
hearing loss to date, with 75-80% of these exhibiting recessive inheritance 8. 
Although deafness is a highly heterogeneous condition, it has been found that mutations in
the Gap Junction Beta 2 (GJB2) gene, encoding connexin 26, are responsible for up to 50%
of cases deafness in populations of Europeans descent 9. The major mutations in GJB2 have
been seen to be population specific,, resulting from founder effects. These include c.35delG
affecting  Caucasians10,  c.167delT  affecting  those  of  Ashkenazi  Jewish  ancestry11 and











in  Africans  or  African  Americans  is  not  a  major  contributor  to  deafness  in  these
populations. Studies have reported pathogenic  GJB2 mutations in up to 37% of alleles9
while in the Kenyan and Sudanese populations less than 4% of variants were found to occur
in the coding region of GJB213 and none at all were found in South Africans14. 
The aim of this study was to ascertain the significance of mutations in GJB2 in a selected
group of Cameroonian and South African patients with non-syndromic deafness.
MATERIALS AND METHODS Ethical Considerations
The study was approved by the Cameroon National  Ethics  Committee (ethics  approval
N°123/CNE/SE/2010) and the  Human Research  Ethics  Committee  of  the University of
Cape Town (ethics approval HREC REF: 080/2011). Written and signed informed consent
was obtained from all participants aged 18 years old or more, or from the parents/guardians
with verbal assent from the children.
Settings, Patients and Controls
Cameroonian Patients were recruited from seven of the ten regions of Cameroon, mainly
from schools  for the deaf,  and those procedures  have been reported previously7.  South
African patients, all from the Xhosa ethnic group, were recruited from Efata School for the
Blind and Deaf in the Eastern Cape Province, South Africa.
During recruitment, information on participants’ medical and family history was obtained
from the participants themselves, their parents and medical records, depending on which
sources  were  available.  In  the  majority  of  cases,  general  systemic  and  otological











audiometry  or  auditory  brain  stem  response  test.  Audiological  test  results  that  were
obtained before admission to schools for the deaf were also reviewed for some subjects.
When  syndromic  deafness  was  suspected,  additional  tests,  when  possible,  were  later
performed to confirm or exclude the diagnosis.
 We included (1) Patients of Black African descent with non-syndromic hearing loss, as
confirmed by a clinical or audiological report, with deafness of either (2) putative genetic
origin,  as  revealed  by  one  or  more  affected  family  members  or  consanguinity,  or  (3)
unknown origin, and who consented to participate in the study. We excluded patients with
syndromic hearing loss and those with obvious environmental causes such as meningitis,
rubella, mumps, measles, severe prematurity and/or birth weight less than 1500g, neonatal
hyperbilirubinemia, neonatal asphyxia, ototoxicity, severe head trauma. 
Following the above selection criteria, a total of 180 Cameroonian patients from a large
cohort previously reported7 and 25 South African patients. 
Normal  hearing  individuals  from  the  same  population  background  as  patients  were
recruited: 17 South African and 64 Cameroonian controls.
DNA Amplification  and Mutation Analysis
At the Molecular Diagnosis Laboratory of the Gyneco-Obstetric and Paediatric Hospital of
Yaoundé, Cameroon, genomic DNA samples were extracted from peripheral blood of the
patients,  following  instructions  on  the  available  commercial  kit  (Puregene  blood  Kit®
(Qiagen,  USA)).  At  the  Division  of  Human  Genetics,  Faculty  of  Health  Sciences,
University of Cape Town, a modified version of the salting out method was used to extract
DNA from peripheral blood specimen of South African patients15, or DNA was purified












The GJB2 gene was amplified following the method of Liu et al. 16. Primers were validated
using BLAST® and primer analysis software. The complete coding region of exon 2 was
amplified  with  the  aforementioned  primers  and then  sequenced  using  an  ABI  3130XL
Genetic Analyzer® (Applied Biosystems, Foster City,  USA), in the Molecular Research
Laboratory in the Division of Human Genetics, University of Cape Town, South Africa.
Bioinformatic and Statistical Analyses
Chromatogram files were manually checked using FinchTV 1.3.1 (GeoSpiza) and aligned
in BioEdit 7.0.5.3 to the GJB2 reference sequence (Ensembl transcript ENST00000382848
(GJB2-001) retrieved 31 August 2012). Detected variations were checked against dbSNP17,
and the effects of non-synonymous mutations were predicted using Polyphen-218.  SHEsis
(http://analysis2.bio-x.cn/  ) was used to analyse for statistical differences allele, genotype
and haplotype frequencies between the cases and controls, as well as the analysis of linkage
disequilibrium9,20. The Chi-square test and the Fisher’s exact test were used to compared
SHEsis results, and a p-value less than 0.05 was considered statistically significant.
Data for the sequenced region of GJB2 was downloaded from the 1000 Genomes browser
(http://browser.1000genomes.org)  for  all  available  populations  [21].  A phylogeny  was
constructed  with  PopTree  software  using  the  Neighbour  Joining  algorithm,  Nei's  DA
genetic  distance22 and  1000  bootstraps.  Principle  Components  Analysis  (PCA)  was
performed in R23 using the FactorMineR Package and the same 1000 Genomes Project data.
As the 1000 Genomes Project data is from apparently healthy individuals, only control data













Table 1 summarizes the socio-demographic data of the study participants. Of the 47 familial
cases (26.1%) amongst the Cameroonian participants, our analysis includes two cases of
two affected siblings, two cases of three affected siblings and one case of four affected
siblings(supplementary data 1). Consanguinity was not reported in the South African cohort
but 10 (5.6%) Cameroonian patients were from known consanguineous unions. Admixture
with other non-African population groups was highly unlikely in all participants.
Clinical Information
Audiological information was only available for patients from Cameroon. Supplementary
data  2  shows  the  severity  of  deafness.  The  majority  of  patients  (70%)  suffered  from
sensorineural hearing loss and a small number (4.4%) suffered from mixed hearing loss.
The type of hearing loss for the remainder of the patients was not determined.
Variations/Pathogenic Mutation Analysis
Two  pathogenic  or  probably  pathogenic  mutations  were  detected  in  two  unrelated
Cameroonian participants, g.3741_3743delTTC (p.F142del)  and g.3816G>A (p.V167M).
Both were detected in only a single individual in the heterozygous state. There were no
pathogenic mutations detected in South African patients.
Sequencing revealed a  number of likely non-pathogenic variants in the  GJB2 sequence
(Supplementary data 3 ) in both Cameroonian and South African patients. We also detected











g.3318-41G>A change occurs in the first intron of GJB2 and the g.3332G>A change leads
to  a  synonymous  mutation.  The most  common variants  in  both  the  South  African  and
Cameroonian  cohorts  were  the  intronic  change  g.3318-34C>T and  two  changes  in  the
5'UTR, g.3318-15C>T and g.3318-6T>A. 
Analysis  with  SHEsis  showed  that  there  were  no  statistically  significant  differences
between  allele,  genotype  or  haplotype  frequencies  between  cases  and  controls  in
Cameroon.  In  South  African  patients,  there  was  a  statistically  significant  difference
between haplotypes (p = 0.023) (Supplementary data 4 ). Linkage analysis showed a low
rate of recombination between our markers but also that they were uninformative of one
another.
Phylogenetics and Principal Components Analysis (PCA)
The phylogeny (Figure 1) shows the populations from the 1000 Genomes Project clustering
into Asians, Africans and Europeans with the admixed populations positioned closer to the
base of the tree. As expected, the South African and Cameroonian controls grouped with the
other  African  populations.  The PCA explains  40% of  the  variation  between population
groups  (Figure  2)  and  that  different  populations  are  characterised  by  different  SNPs
(Supplementary data 5).
DISCUSSION
This  comprehensive  report  on  the  significance  of  GJB2 mutations  in  deafness  in  two
African  populations  offers  a  substantial  contribution  to  the  literature  on the  topic.  The











Indeed, Cameroon is frequently referred to as "Africa in miniature," because of its central
location on the continent, its many geographical and cultural attributes and the diversity of
its  population  (There  are  more  than  200  distinct  local  languages  in  the  country).  The
country spans two main geographical zones of almost equal size: the equatorial rain forest
in the south and the tropical savannah and the Sahel region in the north. At the genetic
level, Cameroonian population diversity mimics that of various ethno-linguistic groups in
African populations24 and it is anticipated that, results from a carefully selected sample in
this  population  could  represent  a  snapshot  of  that  of  many  African  populations.
Furthermore, we included patients from the Xhosa population of South Africa, a formerly
unstudied offshoot of the Bantu population that migrated from areas around Cameroon24.
To our knowledge, the present study is the first to have conducted a comparison of African
GJB2 sequences with the data from the 1000 Genomes Project and revealed the variation
between population groups. This unique finding has emphasised the hypothesis that the
prevalence of mutations in GJB2 in non syndromic deafness amongst European and Asian
populations  is  due  to  founder  effects  arising  after  these  individuals  migrated  out  of
Africa10,11,12,  and not to a putative “protective” variant in the genomic structure of GJB2 in
Africans. Moreover, the exception to this low prevalence of  GJB2 mutations in African
patients with deafness, is a specific mutation, p.R143W (c.427C>T), occurring at a high
rate in the Ghanaian population from Adamarobe village25. This could also be attributed to a
founder effect as this mutation has not been reported in other African populations but has
been reported only in few African Americans (Table 2), who were probably brought from
Ghana during the slave trade. In addition, the description of de novo p.Asp50Asn mutation,
in two Cameroonian patients diagnosed with KID syndrome also confirms that mutations in











comparable to that of other world populations, since de novo p.Asp50Asn mutation is the
most prevalent in KID syndrome globally27.  
Our results both build on the previously published studies of GJB2 deafness in Africa while
distinguishing  itself  with  comprehensive  bioinformatic  analyses  and  a  comprehensive
review. This study will both add to the literature and could influence molecular diagnosis of
hearing loss on the continent. 
Globally, studies have found that pathogenic GJB2 mutations account for 14.2% of alleles
in Japan28 , 18% in Iran29 , 22% in the USA30 and 37% in Italy and Spain9. In contrast, we
found GJB2 mutations in less than 1% of Cameroonian and 0% of South African alleles.
Similar to Africans, Caribbean Hispanics, probably due to their African ancestry, do not
show a large contribution to deafness from  GJB2 variations31.  Mutations in  GJB2 were
unable to explain deafness for any of the African patients, with non-syndromic hearing loss
included in this study. This is similar to other African studies, which have also reported low
frequencies of deafness-associated mutations (Table 2). The pathogenic p.F142del mutation
has been detected and associated with deafness twice before, in the heterozygous state in an
Egyptian patient suffering from moderate hearing loss32 and in four Chinese patients with
non-syndromic hearing loss33. p.V167M has been reported in three studies, only  in patients
of African ancestry. It has been detected in a heterozygous state in 4/406 (~1%) Kenyans
with prelingual, non-syndromic hearing loss13, 1/94 (~1%) African American controls34, and
in 1/19 (~5%) patients from a predominantly African American cohort of patients  with
congenital CMV infection and hearing loss35. While it may be pathogenic, it has not been
reported in a homozygous form and predictive tools give ambiguous results. Polyphen-218
predicts it as "possibly damaging with a score of 0.618 (sensitivity: 0.87; specificity: 0.91)"











0.82)" with HumVar. The Polyphen-2 score shows the probability that a specific change
will be pathogenic.
Three common variants were detected in our cohort,  all of which have previously been
reported at high frequencies in African populations. These are the g.3318-34C>T, g.3318-
15C>T and g.3318-6T>A changes,  which  occured  in  60%,  28% and 4% of  our  South
African  patients  respectively  and  47%,  8%  and  2%  of  our  Cameroonian  patients
respectively. Our results are similar to those of Kabahuma et al. where g.3318-34C>T and
g.3318-15C>T were the only mutations detected in 182 cases and 63 controls from the
Limpopo province, South Africa. The authors described the g.3318-34C>T change in 46%
and 42% of patients and controls respectively and the g.3318-15C>T change in 21% and
35% of patients and controls respectively14. The same variants, including the g.3318-6T>A
change, were also present in deaf individuals from both Kenya and Sudan13; the g.3318-
34C>T and g.3318-15C>T changes in 12.73%, 6.45% of patients respectively. The g.3318-
6T>A change was only found in 0.49% of Kenyan patients.
These variants appear to be almost exclusive to those of African ancestry,  perhaps best
demonstrated by the control data of Tang et al., which is stratified by ethnic background36.
The results show g.3318-34C>T, g.3318-15C>T and g.3318-6T>A occurring in 28%, 3%
and 2% respectively of African Americans but just 3%, 2% and 0% of Hispanics and none
of the variations occurring in either Asians or Caucasians. Tang et al. also found a lack of
polymorphisms  in  the  coding  region  of  African  Americans  but  a  high  prevalence  of
variations in the 3'UTR, an area we did not examine.
There has been one previous study of GJB2 and hearing loss in Cameroon whose results are
partially supported by this  study37.  Out of 67 deaf and 66 normal hearing controls two











c.296insT variant in one control. However, the  Trotta et al. study was limited to a single
school in the North of the country. 
PCA offers a number of SNPs that appear to differentiate African populations from others
included in the 1000 Genomes Project data (Supplementary data 5). Many SNPs occur at
either very low frequencies or just single populations. The three SNPs that we found at a
high prevalence appear to be a reliable way to distinguish African from other populations.
Although we see a difference in haplotype frequencies between cases and controls in South
Africa, that result could easily be due to the low sample size. None of the variants seen in
the South African cohort are known to be pathogenic, making their connection to deafness
unlikely.  All the other tests for significance fail  to find a difference between cases and
controls in South Africa and Cameroon, supporting the hypothesis that GJB2 does not play
a significant role in deafness in Africans.
Study Limitations
The  molecular  methods  described here  only amplified  the  coding  region  of  GJB2 and
cannot detect non-coding mutations elsewhere in the gene. A further limitation is the poor
clinical  description  of  the  South  African  participants  which  may  have  resulted  in
inappropriate inclusion of some of them. However, despite these limitations, the careful
phenotyping and the diversity of the Cameroonian samples, adding to previous data and the
bioinformatics analysis performed in this study strongly validates our findings.
Practice Implications
Our results support the currently published literature and the hypothesis that mutations in











genetic  testing  of  GJB2 in  African  patients  with  non-syndromic  hearing  loss  is  not
recommendable in clinical practice. 
Research Recommendations
The identification of the causal  mutations  in  families  with hearing loss,  using classical
single  genes  screening approaches,  is  difficult  and expensive  due  to  the  heterogeneous
nature  of  non-syndromic  hearing  loss.  It  could  be  appropriate  to  move  to  explore  the
involvement  of  GJB6, the second biggest  cause of  genetic  deafness  in  some European
populations38 or GJA1, which is sometimes used for clinical screening in South Africa.
Another option is to explore our cohort with high-throughput sequencing using platforms
like  OtoSCOPE®,  which  combines  targeted  genomic  enrichment  and  next  generation
sequencing to examine 66 deafness genes at once39. Probably the most efficient perspective
for this study is to use whole exome sequencing, which has proven successful at elucidating
the causes of deafness in a variety of genes and populations, even in small families40, 
In  conclusion,  our  results  confirm that  GJB2 is  not  significantly  associated  with  non-
syndromic deafness in Africans and support that investigation of GJB2   is unnecessary in
most African patients with non-syndromic deafness.
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Figure 1. Phylogeny constructed from 1000 Genomes and study control data. 
 The phylogeny tree shows the 1000 Genomes various populations’ clusters. As expected,
the South African and Cameroonian controls grouped with the other African populations. 
Numbers  indicate  bootstrap  values  over  1000  iterations.  Population  abbreviations  are:
ASW, Americans of African Ancestry in SW USA; CEU, Utah Residents (CEPH); CHB,
Han Chinese in Beijing; CHS, Southern Han Chinese; CLM, Colombians from Medellin
Colombia; FIN, Finnish in Finland; GBR, British in England and Scotland; IBS, Iberian
population in Spain; JPT, Japanese in Tokyo Japan; LWK, Luhya in Webuye Kenya; MXL,
Mexican Ancestry from Los Angeles USA; PUR, Puerto Ricans from Puerto Rico; TSI,












Figure 2. Principal component analysis (PCA) study and 1000 Genomes populations
with respect to variation in GJB2.
The  PCA  explains  40%  of  the  variation  between  population  groups  and  different
populations are characterised by different SNPs.(supplementary data 5).
Population abbreviations are:  ASW, Americans of African Ancestry in  SW USA; CEU,
Utah  Residents  (CEPH);  CHB,  Han  Chinese  in  Beijing;  CHS,  Southern  Han  Chinese;
CLM, Colombians  from Medellin  Colombia;  FIN,  Finnish in  Finland;  GBR, British in
England and Scotland; IBS, Iberian population in Spain; JPT, Japanese in Tokyo Japan;
LWK, Luhya in Webuye Kenya; MXL, Mexican Ancestry from Los Angeles USA; PUR,
Puerto Ricans from Puerto Rico; TSI, Toscani in Italia; YRI, Yoruba in Ibadan Nigeria;











Table 1. Socio-demographic data of study participants.
Demographic 
South Africa Cameroon
Case (Freq.) Control (Freq.) Case (Freq.) Control (Freq.)
Gender
Male 20 (0.80) 0 (0.00) 94 (0.52) 36 (0.60)
Female 4 (0.16) 6 (0.38) 84 (0.47) 24 (0.40)
Unknown 1 (0.04) 10 (0.63) 2 (0.01) 0 (0.00)
Age
Average 13.95 47.75 11.81 13.53
Unknown 4 (0.16) 8 (0.50) 3 (0.02) 0 (0.00)
Age of onset
Prelingual (<2 years) 3 (0.12) N/A 157 (0.87) N/A
Perilingual (2-4 years) 6 (0.24) N/A 0 (0.00) N/A
Postlingual (>4 years) 3 (0.12) N/A 14 (0.08) N/A
unknown 13 (0.52) N/A 9 (0.05) N/A
Transmission
familial 5 (0.20) N/A 47 (0.26) N/A
sporadic/unknown 20 (0.80) N/A 133 (0.74) N/A
N=25 N=16 N=180 N=60












Table 2. Comparison of results between selected studies of GJB2 in African populations.
Variation Country (Observed/Total alleles)
Genomic Coding Pathogenicity Cameroon Ghana& Kenya/Sudan$ South Africa African American
g.3318-41G>A c.-41G>A Polymorphism 1/360*
g.3318-35T>G c.-35T>G Polymorphism 1/1178
g.3318-34C>T c.-34C>T Polymorphism 100/360* 85/1178 19/50*, 119/364@
g.3318-15C>T c.-15C>T Polymorphism 15/360* 38/1178 7/50*, 56/364@ 1/46+, NA+
g.3318-6T>A c.-6T>A Polymorphism 4/360* 2/1178 1/50*
g.3332G>A c.15G>A Polymorphism 1/360*
g.3352_3353insG c.35dupG Pathogenic 1/730
g.3352delG c.35delG Pathogenic 10/1178 7/100~
g.3395C>T c.78C>T Polymorphism 1/1178
g.3396C>T c.79G>A Pathogenic 2/46+, NA+
g.3419T>C c.101T>C Pathogenic NA+
g.3426G>A c.109G>A Pathogenic 1/1178
g.3455_3460del c.138_143del Pathogenic 1/1178
g.3503C>T c.186C>T Polymorphism NA*, 2/122# 3/1178
g.3512C>A c.195C>A Pathogenic 1/1178
g.3542G>T c.225G>T Polymorphism 1/360*
g.3553T>C c.236T>C Pathogenic 1/730
g.3566C>G c.249C>G Pathogenic 1/100~
g.3586_3587insT c.269_270insT Pathogenic NA#
g.3627A>C c.310A>C Polymorphism 1/1178
g.3658A>G c.341A>G Pathogenic NA+
g.3697G>A c.380G>A Pathogenic 1/1178
g.3741_3743delTTC c.424_426delTTC Pathogenic 1/360*












g.3774G>A c.457G>A Polymorphism 2/1178 NA*
g.3795G>A c.478G>A Pathogenic 1/1178 NA+
g.3816G>A c.499G>A Pathogenic 1/360* 4/1178 NA+
g.3850T>C c.533T>C Pathogenic 4/730
g.3868G>A c.551G>A Pathogenic 1/730
g.3906G>T c.589G>T Pathogenic 1/730
g.3925-3926delinsAA c.608_610delinsAA Pathogenic 2/730
g.3958C>T c.641T>C Pathogenic 1/730
NA refers to variations that were found during the study but only in the control group. Variant information was obtained through the relevant
paper's  own  results  and  a  combination  of  the  Deafness  Variation  Database  (http://deafnessvariationdatabase.org/) and  The  Connexin-
Deafness  Homepage  (http://davinci.crg.es/deafness/index.php).  Study references:  *This  study,  #Trotta  et  al.,[37] @Kabahuma et  al.,[14]
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Supplementary data 2. Severity of hearing loss in the Cameroonian cohort.
Level of Deafnessα Left Ear (Freq.) Right Ear (Freq.)
Severe 1 (71-80) 6 (0.03) 7 (0.04)
Severe 2 (81-90) 19 (0.11) 20 (0.11)
Profound 1 (91-100) 53 (0.29) 54 (0.30)
Profound 2 (101-110) 49 (0.27) 46 (0.26)
Profound 3 (111-119) 17 (0.09) 22 (0.12)
Total (120) 7 (0.04) 2 (0.01)
Unknown 29 (0.16) 29 (0.16)
N=180 N=180













Supplementary data 3. GJB2 variations detected and the frequency of the change in South African and Cameroonian cohorts.
Genomic Coding Protein Domainαα RS number Pathogenicity
South Africa Cameroon
Cases (Freq.) Controls (Freq.) P-value Cases (Freq.) Control (Freq.) P-value
g.3318-41G>A c.-41G>A NA Intron Novel Polymorphism 0 0 NA 1 (0.003) 0 0.563
g.3318-34C>T c.-34C>T NA Intron rs9578260 Polymorphism 19 (0.380) 7 (0.219) 0.126 100 (0.278) 40 (0.333) 0.246
g.3318-15C>T c.-15C>T NA 5'UTR rs72561725 Polymorphism 7 (0.140) 1 (0.031) 0.106 15 (0.042) 7 (0.058) 0.450
g.3318-6T>A c.-6T>A NA 5'UTR rs148136545 Polymorphism 1 (0.020) 0 0.421 4 (0.011) 1 (0.008) 0.795
g.3332G>A c.15G>A p.T5= IC1 Novel Polymorphism 0 0 NA 2 (0.006) 0 0.413
g.3503C>T c.186C>T p.N62= EC1 Reported Polymorphism 0 0 NA 1 (0.003) 0 0.563





p.F142del TM3 Reported Pathogenic 0 0 NA 1 (0.003) 0 0.563
g.3774G>A c.457G>A p.V153I TM3 rs111033186 Polymorphism 0 1 (0.031) 0.209 0 0 NA
g.3816G>A c.499G>A p.V167M EC2 rs111033360
Possibly 
pathogenic
0 0 NA 1 (0.003) 0 0.563
N=50 N=32 N=360 N=120












Supplementary data 4. Haplotype frequencies in the South African cohort.
Haplotypeααα Case (freq.) Control (freq.) P-Value
C C T A 0.00 (0.000) 1.00 (0.031) 0.209
C C T G 24.00 (0.480) 24.00 (0.750) 0.016
T C T G 19.00 (0.380) 6.00 (0.188) 0.065
T T T G 0.00 (0.000) 1.00 (0.031) 0.297
C T A G 1.00 (0.020) 0.00 (0.000) 0.421
C T T G 6.00 (0.120) 0.00 (0.000) 0.042
Global 0.030
αααHaplotypes were constructed from the following SNPs: g.3318-34C>T, g.3318-15C>T,
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Background: Deafness  is  the  most  common sensory disability in  the  world and has  a
variety of causes. Globally, mutations in  GJB2 have been shown to play a major role in
non-syndromic deafness, but this has not been seen in Africans. Two other connexin genes,
GJB6 and GJA1, have been implicated in hearing loss but have been seldom investigated.
Methods: We recruited a subset of 100 patients from a cohort that was previously shown
not to have  GJB2 deafness and Sanger sequenced the full  coding regions of  GJB6 and
GJA1. In addition, we checked for the large-scale GJB6-D3S1830 deletion.
Results: No pathogenic mutations  were detected in  either  GJB6 or  GJA1,  nor was the
GJB6-D3S1830  deletion  detected.  There  were  no  statistically  significant  differences
between patients and controls. 
Conclusion: Mutations in  GJB6 and  GJA1 are not a major cause of deafness in African
populations and we advise against using them for clinical screening.












Deafness is one of the leading causes of disability in the world and is most severe in the
developing world.[1] It is a highly variable and extremely heterogeneous condition that can
range from mild to total hearing loss and present either as a single symptom or as one of
many clinical  features.  Deafness  can  be  caused  by environmental  conditions,  genetics,
normal aging or a combination of factors.
At  current,  65  different  genes  have  been  identified  that  contribute  to  non-syndromic
deafness and there are many more causative mutations.[2] Mutations in  GJB2 (connexin
26) have been shown to be a major contributor to deafness globally but, with the exception
of Ghana, not in sub-Saharan Africa.[3] Other potential candidate genes that could lead to
non-syndromic deafness in Africans are GJB6 (connexin 30) and GJA1 (connexin 43).
The second biggest genetic cause of deafness in the European population is  the  GJB6-
D13S1830 deletion identified by del Castillo et al.[4] and present in up to 9.7% of patients
in  some European countries.[5] Although originally considered to  be a  case  of  digenic
inheritance, as connexins 26 and 30 are known to interact, other evidence suggests that the
deletion includes an unidentified cis-regulatory region for GJB2.[6] 
GJA1 emerged  as  a  possible  candidate  for  hearing  loss  in  Black Africans  when  GJA1
mutations  were  detected  in  African  Americans.[7] Those results  were  due  to  failure  to
differentiate between  GJA1 and its pseudogene and the changes were only present in the
pseudogene.[8] Subsequent  studies  of  GJA1 and  hearing  loss  have  either  found  no
causative variants or variants at very low frequencies.[9–12] 
Variations in both GJB6 and GJA1 are checked for clinical screening in South Africa and
the GJB6-D13S1830 deletion is the second largest global cause of non-syndromic hearing
loss. We aimed to validate the utility of testing for GJB6 and GJA1 in an African context.
Methods
Ethical Considerations:
Recruitment  of  patients  from Cameroon  was  approved  by Cameroon's  National  Ethics
Committee, authorisation number N°123/CNE/SE/2010. Ethics approval for the GJB6 and
GJA1 research was granted  by the University of  Cape Town's  Human Research Ethics











informed consent was obtained from all participants, if they were 18 years or older, or from
the parents/guardians with verbal assent from the children. 
Patient Selection:
A subset of 100 patients from our earlier study (Bosch et al., unpublished data) was chosen
in order to maximise the probability of finding a genetic cause of deafness. Our cohort
included  six  consanguineous  Cameroonian  patients,  52  familial  (including  four
consanguineous) Cameroonian cases, five familial South African cases, two patients with
heterozygous  GJB2 mutations,  15  prelingual  Cameroonian  cases  and  the  20  remaining
South African cases. All but four Cameroonian patients had previously been genotyped for
GJB2. 
Methods:
Detection  of  del(GJB6-D13S1830)  was  performed  using  the  primers  described  by  del
Castillo  et  al.[4,5] The  entire  coding region  of  GJB6 was  amplified  using  the  method
described by Chen et al.[13] A 1348 bp fragment consisting of the entire  GJA1 coding
region was amplified using the F1 and R3 primers described by Huang et al.[14] Amplified
products were Sanger sequenced, in both the forward and reverse direction,  on an ABI
3130XL Genetic Analyser (Applied Biosystems, Foster City, USA). The same primers were
used  for  amplification  and  sequencing.  Differences  in  allele,  genotype  and  haplotype




The Cameroonian cohort was evenly distributed in terms of gender (46% female) while the
South  African  cohort  was  80%  male.  In  the  Cameroonian  cohort,  94%  of  patients
experience prelingual hearing loss while age of onset was unknown for the majority of the
South African cohort. No information on consanguinity was available for the South African
cohort but 10 patients in the Cameroonian cohort were from consanguineous marriages.
There was no audiological information available for the South African cohort but all the
Cameroonian patients presented with severe or greater (≥71 db) bilateral hearing loss. The













Two Cameroonian patients failed to amplify for both  GJB6 experiments. None of the 98
patients had  the GJB6-D13S1830 deletion. Only one variant (rs145762940) was detected,
in  the  heterozygous  state,  in  the  coding  region  of  GJB6, leading  to  the  synonymous
c.480G>A change. No variations in GJB6 were detected in 31 controls (12 South African
and 19 Cameroonian).
GJA1:
Two South African and eight Cameroonian patients failed to amplify for  GJA1 and were
excluded. Five variants were detected in  GJA1 (Table 1), one of which occurred in the
intron,  but  none  of  which  are  known  to  be  pathogenic.  Forty-one  controls  (17  South
African, 24 Cameroonian) were also sequenced but only the synonymous c.717G>A change
was detected. In addition, there were no statistically significant differences between cases
and controls.
Discussion
Like  previous  studies  in  Africans,[17] as  well  as  studies  in  Chinese,[13] Indians,
[18] Turkish[19] and  both  African  American  and  Caribbean  Hispanics  with  GJB2
mutations,[20] we  did  not  find  either  the  GJB6-D13S1830  deletion  or  coding  region
changes. This supports the hypothesis that the GJB6-D13S1830 deletion is the result of a
founder effect.[5] In addition, there remains little evidence for coding region variations in
GJB6 that lead to deafness.
Although variants were detected in  GJA1 there were no significant differences between
patients and controls. We have identified the novel c.366T>C (p.=) GJA1 variant (Figure 1)
which has not, to our knowledge, been described before. Only one variant, the c.758C>T
(p.(A253V)) change, was non-synonymous. However c.758C>T is a known change that is
not considered to be pathogenic. It has been reported both in cases and controls in various
studies on  GJA1[10,21–23] but has been suggested to modify disease severity in certain
cases.[24] 
As the two major genetic causes of global non-syndromic deafness, GJB2 and GJB6, have











least 65 candidates,[2]  we recommend that future research should take advantage of the
power of massively parallel sequencing to screen multiple genes at once. This approach has
previously been shown to be effective for non-syndromic deafness[25] and offers the best
chance of uncovering the genetic causes of deafness in a setting with a genetically diverse
population.
Conclusion And Perspective
We did  not  find  evidence  that  mutations  in  either  GJB6 or  GJA1 are  linked  to  non-
syndromic deafness in sub-Saharan African patients. We recommend against using either
gene for clinical testing in patients of African ancestry. 
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c.-67A>G NA rs189167598 0 0 NA 0 0 0.547
c.189T>C p.= EC1 rs139688042 0 0.384 0 0 0 NA
c.366T>C p.= IC2 Novel 0 0.384 0 0 0 NA
c.717G>A p.= IC3 rs57946868 0.397 0 0.332




















































































Figure 1: Novel GJA1 variant, c.366T>C (p.=) detected in one South African patient.
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